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ABSTRACT OF DISSERTATION 
 
 
 
A COMPARISON OF UPPER EXTREMITY FUNCTION BETWEEN FEMALE 
BREAST CANCER SURVIVORS AND HEALTHY CONTROLS:  TYPICAL SELF- 
REPORT OF FUNCTION, MOTION, STRENGTH AND MUSCULAR ENDURANCE 
 
  
Many women who have experienced breast cancer (BC) report continued 
impairments in upper extremity (UE) function beyond the time required for normal 
healing after surgical treatment.  Most research supporting this has not made comparisons 
between survivors of breast cancer (BCS) to a sample of healthy women.  This lack of 
comparison to a healthy cohort prevents an understanding of whether continued deficits 
in UE function are due to normal aging or the BC treatment.   
 
The purpose of this research was to compare quality of life (QOL) and UE 
function among long term breast cancer survivors and similar aged women without 
cancer.  Both self-report and objective measurements of UE function were used to create 
an understanding of UE functional abilities in both populations.   
 
Data on self-reported QOL and UE function, ROM, strength, and muscular 
endurance were collected on 79 healthy women ages 30-69, stratified by decade.  
Comparisons between decades and between dominant and non-dominant limbs were 
made.  Findings supported no effect of aging on measures, and that dominance does 
affect some objective measures of motion, strength, and muscular endurance.   
 
A group of 42 survivors of breast cancer (BCS) were compared to the data from 
healthy controls on the same measures.  BCS reported lower levels of QOL and UE 
function, and demonstrated less motion and strength than the healthy cohort, particularly 
when cancer occurred on the non-dominant limb.  The values of the measures, however, 
are not clinically relevant, and reveal that BCS 6 years after treatment recover UE 
function to levels similar to healthy controls. 
 
In view of a lack of clinically feasible measures of UE muscular endurance, a new 
test to assess this was designed and implemented: the modified Upper Body Strength and 
Endurance test (mUBSE).  It was believed this new test would be less variable than the 
 
 
Functional Impairment Test – Hand and Neck, Shoulder, Arm – FIT-HaNSA.  Seventeen 
BCS and 17 matched controls were compared on the mUBSE and FIT-HaNSA.  Findings 
were similar for both tests.  Furthermore, BCS who are 6 years post BC treatment appear 
to recover muscular endurance levels to normal ranges. 
  
 
KEYWORDS:   Breast cancer, quality of life, upper extremity function, range of motion 
and strength, muscular endurance 
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CHAPTER ONE 
Breast cancer is the most common non-skin cancer among women, with a lifetime risk of 
1 in 8.1  Approximately  226,870 women will be diagnosed with breast cancer (BC) in 
2012 alone.2  Over the last 25 years, survival rates have increased to 90%; current 
estimates are that over 2.5 million women are living with BC.1  As the number of women 
living beyond diagnosis and treatment of BC has climbed, the focus of research and 
intervention is expanding to include quality of life (QOL) issues for survivors. 
Activity limitations and participation restrictions among survivors of breast 
cancer (BCS) can be attributed to physical declines reported on QOL scales.  Physical 
function scores decline the greatest immediately following surgical treatment for breast 
cancer, but remain below baseline 6-104 weeks after treatment.3,4  These deficits are 
greater among women who undergo more involved interventions such as axillary lymph 
node dissection or mastectomy surgeries, or axillary radiation, than the less invasive 
lumpectomy or sentinel node biopsy.5,6   
The link between activity limitations and participation restrictions, and QOL may 
be explained by changes in upper extremity (UE) function after BC treatment.   Full UE 
function is dependent upon adequate motion, strength, and muscular endurance to 
complete a particular task.7  Women diagnosed with BC frequently have upper extremity 
functional deficits associated with treatment including loss in motion and strength in the 
arm, resulting in activity limitations.8-13  Less is known about the extent of change in 
muscular endurance and its impact on UE function.14-16 
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Self-Report of Function of BCS 
Researchers have provided evidence of moderate to high levels of UE self-
reported disability among women treated for BC.  In a long term study following 188 
BCS, the Disabilities of the Arm, Shoulder, and Hand (DASH) was used to determine the 
extent of upper body functional impairment.17 Scores of greater than 20 on the DASH 
were categorized as poor upper body function.  At 6 months following BC treatment, 
25.6% of BCS scored greater than 20, and at a 6 year follow-up, 21.1% continued to 
score greater than 20.17  Other studies examining the self-reported level of UE function 
have documented mean DASH scores ranging from 24 to 32 in BCS 1-360 months 
following treatment.18,19  This continued report of UE functional impairment more than 5 
years after BC treatment suggests that this is an issue that the medical community should 
address during the acute recovery phase to facilitate resumption of normal levels of 
function.   
Understanding how the level of self-reported function among long term BCS 
compares to a healthy population may clarify whether persistent functional disability is 
due to BC treatment or occurs with normal aging.  One such study which used the DASH 
to compare self-reported levels of disability of a group of BCS at 6 months following 
treatment to a healthy control group found significantly more disability in the BC group 
(19.4±17) than the control group (1.6±1.7).9  This comparison between BCS and a group 
of healthy women has not been done for BCS more than 12 months beyond BC treatment.  
To better understand persistent functional disability however, it is important to know 
whether the report of disability long term is due to BC treatment or normal aging. 
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Objective Measures of UE Function among Survivors of BC 
Range of motion (ROM) and strength are integral to normal UE function.  These 
objective measures of UE function have been examined in BCS within the first year 
following diagnosis and treatment.  Diminished motion8,11,14,20 and strength8,14,16 of the 
involved extremity have been documented in comparison to the non-involved side.  The 
same  limitation exists for  these data as the self-reported function in that the changes 
seen compared to the contralateral limb may not be long term, but rather due to the 
necessary healing time required following surgical and radiation treatments.  
Furthermore, limited data exist comparing the UE function among BCS in the short term 
to a population of healthy controls.  One study has compared UE function of 24 BCS less 
than 6 months from surgical intervention to matched controls, and reported significant 
but small motion deficits ranging from 5-11°, and moderate strength deficits of greater 
than 20%.9  It is unknown if these deficits persist beyond 6 months when compared to a 
healthy cohort.  A study comparing long term BC survivors to a similar population of 
healthy controls would help to determine whether these deficits are present beyond the 
first year following BC treatment, and provide information on the long term effects of 
breast cancer treatment on UE function.  
The prevalence of fatigue associated with BC treatments has been as high as 61-
99% in all BCS,21 with 41% of BCS reporting fatigue 2-5 years after diagnosis.22   This 
near universal complaint would suggest that muscular endurance has not been restored 
following BC interventions. Furthermore, diminished muscular endurance can impact UE 
function.7 Muscular endurance is an essential component of UE function, yet has been 
minimally studied among BCS.  Two studies have examined muscular endurance of the 
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involved UE compared to the contralateral limb in BCS.  Within the first 6 months of 
treatment among BCS undergoing surgical treatment, muscular endurance was altered by 
20% in the involved limb.14  In another study of study of 40 BCS with a mean duration 
since treatment of 28 months, no deficits in muscular endurance were found in the 
involved extremity when compared to the non-involved side.16  These findings suggest 
that BCS recover muscular endurance over time however, this latter study may have 
biased recruitment of muscle fibers toward fast twitch, calling into question whether the 
test actually assessed muscular endurance.  More importantly, neither study made a 
comparison to a healthy population; therefore a determination cannot be made whether an 
inequality in muscular endurance is due to an inherent difference between arms, due to 
aging, or is a result of pathology.   
Problem 
Quality of life is often compromised following breast cancer treatment in the short 
term, and is commonly associated with UE functional deficits.  Long term deficits in 
motion and strength have been reported following treatment for BC, although the 
prevalence of deficits declines from the short term.10,12,15,20 Furthermore, questions arise 
regarding the extent of the deficits which persist beyond the first year after treatment and 
how these may affect overall UE function, but it is reasonable to expect these deficits are 
sustained in the long term to some degree.  No study has directly compared healthy 
women to BCS using objective measures of upper body motion, strength, or muscular 
endurance at 12 months or more after surgical intervention. Comparison to a healthy 
population allows a determination whether UE deficits are due to cancer and subsequent 
treatments, or due to the natural aging process.  
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Purpose 
The primary purpose of this research is to compare quality of life and UE function 
among long term breast cancer survivors and similar aged women without cancer.  Both 
self-report and objective measurements of UE function are used to create an 
understanding of UE functional abilities in both populations.   
Hypotheses 
1a) Self-report of QOL and UE function will be lower among a group of BCS compared 
to healthy controls of the same age. 
1b) Motion, strength, and muscular endurance will be less on the involved limb in women 
with BC compared to same limb in women without BC. 
1c) Motion, strength, and muscular endurance will be less on the involved limb than the 
non-involved limb in women treated for BC.  
The second purpose is to determine if UE function declines across the normal 
aging process, and whether ROM, strength, and muscular endurance differ based on limb 
dominance.    
Hypotheses 
2a) Motion, strength, and endurance measurements will decline with aging among a 
healthy population of women stratified by decade from 30’s to 60’s.  
2b) The dominant limb of healthy women ages 30-69 will demonstrate greater strength 
and muscular endurance than the non-dominant limb. 
2c) The dominant limb of healthy women ages 30-69 will demonstrate decreased 
shoulder mobility than the non-dominant limb. 
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The third aim of this dissertation is to investigate and compare clinical measures 
of muscular endurance in order to identify a measure that has good responsiveness and 
minimal ceiling effects.  
Hypothesis 
3) The modified Upper Body Strength and Endurance test (mUBSE) will be a less 
variable measure of muscular endurance than the FIT-HaNSA. 
Operational Definitions 
For the purposes of this study, the following definitions were used: 
Estimated 1 repetition maximum (1RM) is a submaximal repetition test used to determine 
a 1RM value.  Each participant was given a heavy load, and the number of repetitions 
correctly performed was counted.  The estimation is based on the following formula 
where x is the number of repetitions completed:23 
Estimated 1RM = weight lifted/(1.0278-.0278x) 
Short term effects are deficits in self-reported QOL and UE function, shoulder motion, 
strength, muscular endurance, present immediately after surgical treatment and which 
resolve within 12 months. 
Long term effects are said deficits lasting greater than 12 months. 
Outcome measures:  
Range of Motion:  Range of motion measured with a goniometer has adequate to good 
intra-rater reliability,24 reported by various authors with ICCs ranging .53-.98.25,26  
Goniometric landmarks were used in this study, however, measurement of shoulder 
flexion, external rotation, and hand behind back (HBB) was be completed using digital 
photography and software to calculate angles and distances.  The (HBB) measure is the 
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distance in centimeters from the C7 spinous process to the spinous process in line with 
the tip of the thumb when the hand is reached behind the back as high as possible.27 
Strength:  Strength of shoulder flexors, internal and external rotators as measured with a 
mean maximal voluntary isometric contraction (MVIC) using hand-held dynamometry 
was completed.7  Strength was then normalized to body weight and reported as a 
percentage of body weight in order to make comparisons among individuals clearer.   
Muscular Endurance:  One measure of muscular endurance is Functional Impairment 
Test - Hand, and Neck, Shoulder, Arm (FIT-HaNSA),28,29  which measures the duration 
of UE lifting and manipulation tasks.  A second test of muscular endurance used is a 
modified Upper Body Strength and Endurance Test (mUBSE), patterned after the Upper 
Body Strength and Endurance Test.14,15   In the mUBSE, the participant repetitively lifted 
50% of her estimated 1RM until one of 4 stopping criteria were met: 
1. Participant could no longer continue lifting weight 
2. Participant could not reach her maximum high point of elevation 2 times 
consecutively 
3. Participant could not maintain cadence of lift (2 beats up/2 beats down) 
4. Participant demonstrated extremely poor form of lift 
The number of repetitions and the duration of the test in seconds for each limb were 
recorded. 
Assumptions: 
1. All participants accurately reported no current (within the last 6 months) shoulder, 
cervical or thoracic pathology. 
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2. All participants accurately reported no surgery to the shoulder, cervical or 
thoracic spines, other than that related to BC treatment. 
3. All BCS underwent a mastectomy and/or axillary lymph node dissection and/or 
axillary radiation. 
4. All participants gave their best effort during measurements of strength, motion, 
and muscular endurance. 
5. All participants accurately completed self-report questionnaires. 
Limitations: 
1. No BCS in their fourth decade were recruited. 
2. Some participants in the study may have been exposed to physical therapy 
intervention in the past, and as a result may have performed differently than those 
who had no previous physical therapy. 
3. The investigators were not blinded to group during data collection, and the 
primary investigator was not blinded to group during data analysis. 
4. Primary recruitment of participants was through BC support groups, possibly 
biasing this sample toward a group of women with higher levels of support or 
resources. 
Delimitations 
1. The healthy control group consisted of females, ages 30-69, with an ability to read 
and write English.   
2. The BCS group was limited to females, ages 30-69 who had been diagnosed with 
BC and completed surgical treatment at least one year prior to enrollment.  
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Surgical treatment must have included at least one of the following: mastectomy, 
axillary lymph node dissection, or axillary radiation. 
3. All participants were excluded if they had recent (6 month) history of shoulder, 
cervical or thoracic spine pathology diagnosed by a physician, or any history of 
shoulder, cervical or thoracic surgery.   
4. Breast Cancer Survivors were excluded if the surgical treatment of BC was 
limited to breast conserving therapy (lumpectomy), or sentinel node biopsy, or 
local (tumor bed) radiation.   
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CHAPTER TWO 
Current literature related to understanding upper extremity (UE) function and evidence of 
UE function among survivors of breast cancer (BCS) is the focus of Chapter Two.  The 
first section presents evidence supporting UE function as an aspect of, and having an 
effect upon, quality of life (QOL).  The link between UE function and QOL within the 
framework of the International Classification of Functioning, Disability and Health (ICF) 
will be established.  The second section presents methods to measure UE function, 
including subjective and objective measurements.  The emphasis is on clinical 
measurements rather than laboratory techniques as these will better inform clinical 
practice.  Lastly, the need for measuring UE function in survivors of breast cancer (BCS) 
is presented with evidence outlining the understanding of UE function in long term BCS. 
Introduction 
Breast cancer (BC) is the most commonly diagnosed non-skin cancer among women, 
with 2012 estimates at more than 280,000 new cases of both invasive and in situ cancer.30  
With a lifetime risk of 1 in 8 women being diagnosed with BC, greater than 67% of these 
cases, will be among women between the ages of 44 and 74.31  Survival rates have 
increased 15% in the last 25 years, and currently approach 90%.31  The number of women 
diagnosed with and surviving BC has placed prevalence estimates at 2.8 million 
women.31 The focus of treatment for BC has broadened from simply focusing on the 
cancer itself to ensuring a return to a QOL similar to the pre-cancer diagnosis time point.  
 The World Health Organization’s ICF7 is a framework to measure and describe 
health and disability, and the impact of health conditions on abilities of an individual, 
within a context of environmental and social structures.  The presentation of health and 
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disability within this context of specific domains is the way in which the ICF codifies the 
impact of disability on QOL. ICF body structure and function domains comprise 
parameters of UE function, including motion, strength, and muscular endurance.7  
Impairments in any of one of these three areas can result in limitations in activity and 
restrictions in participation, also outlined in the ICF.7  The mobility domain under 
activities and participation constructs of the ICF lists carrying, moving, and handling of 
objects and the self-care domain includes abilities related to washing, toileting, dressing, 
eating and drinking.7 All of these tasks require functional abilities of the UE; the inability 
to carry-out tasks within these domains can result in lower reported QOL. 
Physical function is one aspect of QOL.  Most QOL measures include a physical 
functioning subscale within the tool.  The physical well-being subscale on the Functional 
Assessment of Cancer (FACT-G)32 includes questions related to abilities to meet the 
needs of family members.  The FACT-B33 has an additional nine items specific to BCS, 
one of which focuses on arm swelling, or lymphedema, as a result of BC treatment.   
Interference in the ability to use the UE to complete daily tasks can result in lower levels 
of QOL whether from the impact of lymphedema, or impairments related to motion, 
strength, or muscular endurance.3,34 
Given the potential for UE disability following BC treatment and its possible 
impact on QOL, it is necessary to identify impairments in physical functioning so they 
can be effectively addressed. The purpose of this paper is to: (1) review how UE function 
is measured, with an emphasis on measures with clinically feasibility; and, (2) identify 
the reported levels of UE function in long term BCS.  
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Typical Measures of UE Function 
 To accurately understand UE functional abilities, a comprehensive assessment of 
the different components of function is required.  Complete assessment includes 
measuring self-reported function, as well as taking objective measures of range of motion 
(ROM), strength, and muscular endurance.  These measurement tools must be valid and 
reliable to gain a thorough clinical view of UE function.  The following section focuses 
on methods of measurement for each component of UE function, and presents evidence 
related to validity and reliability of the measures. 
Self-report of UE Function 
Clinically, self-report measures are commonly used to describe UE function and 
provide the clinician with important information about an individual’s perception of 
abilities.  Although numerous validated scales have been designed for the UE, those used 
in BC research include the Disabilities of the Arm, Shoulder and Hand (DASH),35 the 
Penn Shoulder Score,36 and the Constant Murley Shoulder Score.37  Another potentially 
useful scale which has not been used in BC research is the Upper Extremity Functional 
Index (UEFI).38  Each of these scales includes specific functional activities on which an 
individual rates her level of difficulty performing a task.  Of these, only the DASH and 
the UEFI provide a framework for assessing function based on ICF constructs, therefore 
providing an understanding UE function within this contextual framework.   
The DASH is a reliable and valid39,40 30 question disability scale which is 
commonly reported in BC research studies.   The DASH scale is scored 0-100, with 
lower scores indicating less disability.  Two studies have examined the items on the 
DASH in relation to the ICF framework and have found good association to the body 
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functions and the activities and participation components of the ICF.41,42  Intraclass 
correlation coefficients (ICC) for test-retest reliability range from .77-.98,39,43 and both 
construct  and convergent validity was established with 3 other shoulder scales: the 
American Shoulder and Elbow Surgeons Score, the Simple Shoulder Test, and the 
Shoulder Pain and Disability Index.43,44  Normative data for the DASH have been 
established for the general United States population using a sample of 1706 participants, 
with a mean of 10.1±14.68 reported.45   The effects of age, gender, and type of 
employment on DASH scores were examined in a study of 716 employed adults in 
Germany, a country with similar a socioeconomic makeup to the United States.46  DASH 
scores increased with age, were higher among women than men (14.3±14.9 and 
11.6±15.8, respectively), and among manual laborers as compared to non-manual 
laborers (15.7±17.2 and 937±12.5, respectively).46   
The Upper Extremity Functional Index (UEFI) has not been used in published 
research to assess self-reported arm function among BCS; however, it was designed with 
the current ICF model as a guide.38  This 20 question scale scores specific functional 
tasks on level of difficulty, from 0 (i.e. extremely difficult) to 4 (i.e.no difficulty).   A 
total of 100% indicates full UE function.  The UEFI has a test-retest reliability of 
ICC=.95, and good convergent validity with the Upper Extremity Functional Score 
(r=.82).38  The questions on this scale pertain specifically to the involved extremity, 
differing from the DASH which asks about the level of difficulty in completing a task, 
regardless of whether the pathological limb is involved in the task. 
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Objective Measures UE Function:  ROM, Strength, and Muscular Endurance 
Objective measures of UE function include range of motion (ROM), strength, and 
muscular endurance.  Methods to quantify these measures include both laboratory and 
clinical methods.  Commonly used clinical tests are reviewed, as well as those less 
common but which provide objective and accurate measures. 
Range of motion in the clinic is frequently measured using several different 
methods: goniometry, photography, and inclinometry.  Goniometry provides the clinician 
with an inexpensive but reliable method to document motion.  In a study of 50 
participants referred to physical therapy, both intra- and inter-rater reliability were 
examined for all shoulder motions.25  In particular, shoulder flexion motion demonstrated 
better intra-rater reliability (ICC = .98) than inter-rater reliability between 2 testers (ICC 
= .89), although both methods demonstrated good reliability.25  In a smaller study of 8 
participants and four raters, the inter-rater reliability of shoulder flexion measured with a 
goniometer was lower (ICC=.69), with a standard error of measurement of 25°.26  This 
lower reported ICC value suggests that reliability between more than 2 testers is more 
difficult to ensure.   
Still photography of a joint presents another option for measuring ROM.  By 
applying a goniometer on the photo to measure motion, or using specialized software to 
measure angles and distances, an exact measurement can be made.  In a study examining 
the reliability of five methods of measuring shoulder ROM, photography with a 
goniometer demonstrated moderate24 inter-rater reliability for shoulder flexion (ICC = 
.73).26  When comparing the inter-rater reliability of the goniometer to photographic 
measurement, the ICCs are similar, but photography appears to have a slightly higher 
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value, suggesting that it may be beneficial to use this method to reduce error in an 
environment where multiple clinicians are involved in care. 
Inclinometry provides the clinician with another method to measure ROM.  The 
intra-rater reliability of inclinometry is reportedly better than goniometry with ICC= .90-
.95.47 However, inter-rater reliability of inclinometry has greater variability as compared 
to goniometry with reported ICCs ranging from .28-.90, and differences of measurement 
between observers exceeding 10°.47  These findings suggest that inclinometry is best used 
by a single examiner rather than in a situation where more than one tester is involved. 
Measuring internal rotation ROM with a goniometer can result in lower inter-rater 
reliability (ICC = .50-.66)48 because controlling for scapular motion is difficult.  In this 
situation, internal rotation ROM measures are often performed in a clinically functional 
manner by having an individual reach her hand up behind her back.  This Hand Behind 
Back (HBB) measure is not a true measure of shoulder internal rotation because it 
incorporates glenohumeral extension, scapular retraction, downward rotation and elbow 
flexion.49,50 However, it does mimic many UE functional motions including dressing, 
reaching into back pockets, or reaching behind, and so is a useful clinical tool for 
determining whether a limitation may impact functional activities.  Furthermore, 
concerns over low inter-rater reliability can be addressed by using photography to capture 
the motion with one individual measuring the motion. 
 In a clinical setting, strength is frequently measured using manual muscle testing 
(MMT). MMT is a subjective method of grading force of resistance on a 0-5 point scale, 
where 0 is no evidence of muscle activity, 3 is full anti-gravity motion without resistance, 
and a 5 is full anti-gravity motion with maximal resistance.51  Intra-rater reliability of 
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MMT has been reported as high as ICC=.98 for shoulder abduction in a study of 11 
participants. 52  Inter-rater reliability is lower; in another study of 11 participants 
measuring deltoid strength, the reported kappa was .62.53  An additional but important 
limitation of MMT is the inability to provide a specific level of force production which 
can be objectively tested and retested over time. Dynamometry can provide a reliable 
objective measure of the level of strength where MMT does not. 
Dynamometry has traditionally been reserved for laboratory research; however, 
the development of hand-held dynamometry (HHD) provides the clinician with a method 
to objectively measure strength.  Concurrent validity of HHD with isokinetic 
dynamometers has been established.54  The reliability of HHD for UE strength testing has 
also been established in multiple studies with ICCs ranging from .82-.97.55-57 Some 
studies have suggested that the counterforce provided by the examiner can influence 
accuracy in measurement. Two studies investigating gender effects in HHD measures 
reported that female testers have lower levels of inter-rater reliability than males as 
greater stabilization is needed for larger muscle groups.58,59 This problem of an adequate 
counterforce can be alleviated by using a consistent stabilization force such as a strap or a 
brace.60,61   Normative data and reference values for hand-held dynamometry have been 
established and are available for comparisons.62,63 
Muscular endurance is an essential component of UE abilities, but because few 
clinical measures exist, it is not often tested. A newer test of muscular endurance is the 
Functional Impairment Test – Hand and Neck, Shoulder, Arm (FIT-HaNSA).29  This test 
examines the ability of an individual to sustain an activity over time in 3 sub-tests of 
repetitive UE use.  These sub-tests include repetitive lifting at chest height, above head, 
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and an overhead manipulation task. The FIT-HaNSA has demonstrated good reliability 
(ICC=.79-.97)28,29 and convergent validity with self-report scales (r=.71-.76),28,29 yet no 
normative values for this test have been reported.   
Another clinical muscular endurance test is the Upper Body Strength and 
Endurance Test (UBSE).14 In the UBSE, the participant completes a combination upright 
row/shoulder press motion repeatedly as resistance is incrementally increased. The test is 
discontinued when the participant can no longer perform the motion correctly, keep a 
specific pace, or stops. The psychometric properties of the UBSE have not been 
investigated, but this test has been used to examine muscular strength and endurance in a 
population of BC survivors.14,15 
Recommended Clinical Measures of UE Function 
 Using valid and reliable tools to measure UE function is important to accurately 
assess functional abilities.  Those self-report measures of UE function that meet these 
criteria include the Penn Shoulder Score (PSS),64 the Constant Murley Shoulder Score 
(CSS),65 and the Disabilities of the Arm, Shoulder, Hand (DASH).39,43,44  Although any 
of these measures could be used, the DASH has been validated in multiple 
populations39,40,43,46 and may be a more versatile tool for clinical use.  Reliable and 
objective clinical measures include goniometry, including photography, or inclinometry 
for ROM, and hand held dynamometry for objectifying strength.  Muscular endurance 
should be a component of clinical assessment of UE function, yet few valid and reliable 
tools are available to the clinician.  The FIT-HaNSA is one such tool which could be 
incorporated into evaluation.  By using a combination of measures, the clinician gains a 
clear understanding of UE functional abilities. 
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UE Function Among Breast Cancer Survivors 
Treating BC can involve extensive surgery to the anterior chest and axillary regions, 
which may impact UE function.  Women who undergo mastectomies and axillary lymph 
node dissection have higher levels of UE morbidities than women who undergo breast 
conserving surgery and sentinel node biopsies.6,10,11,66,67  Axillary radiation treatment can 
result in further declines of UE function.68,69  This section will review the literature 
related to the extent of UE disability and recovery of functional abilities in within and 
after the first year of treatment. 
UE Function 0-12 months following BC Treatment 
Many women treated for BC report that they do not recover to their pre-diagnosis 
level of UE function within the first year after treatment. In a study of 188 BCS 6 months 
after treatment, 25.6% report Disabilities of the Arm, Shoulder and Hand (DASH) scores 
of greater than 20.17  In another study, significantly higher DASH scores were recorded 
by 24 BCS less than one year from treatment compared to matched controls.9  Other 
studies using non-standardized self-report questionnaires confirm the loss of UE function 
for this population.10,70-72  These self-reports of UE functional loss may be the result of 
impairment in the components of UE function, including ROM, strength, and muscular 
endurance, which occur after BC treatment. 
Joint ranges of motion and muscle strength levels have been examined in BCS 
following surgical and adjuvant treatment.  Diminished motion11,14,20 and strength8,14,16  
of the involved extremity have been documented in the first year after BC treatment.  
Deficits of up to 10% of flexion motion and 20% of elevation strength are reported when 
compared to the contralateral limb.8,14  When examining deficits compared to age 
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matched controls, limited data exist.  In a comparison of 24 BCS within 6 months of 
treatment to matched controls, shoulder flexibility deficits ranged from 7-12%, and 
strength deficits reported were up to 27%.9   It is necessary to compare the ROM and 
strength of BCS more than one year following treatment to a population of healthy 
controls to determine if problems persist beyond the healing stage in the first year. 
One study has examined muscular endurance of the involved UE compared to the 
contralateral limb in BCS within 12 months of diagnosis.  Another study examining 
endurance used the Upper Body Strength and Endurance test (UBSE) to record the 
weight of the last successfully completed stage in a progressive resistance lifting task.14  
In contrast to the shoulder press task, the involved limb in the UBSE study showed a 20% 
deficit in muscular endurance compared to the non-involved limb among BCS 6 months 
following surgical treatment.14  In the shoulder press task, the use of 90% of 1RM may 
bias fast twitch fibers and therefore might not accurately reflect muscular endurance.  The 
UBSE measures the maximum weight lifted over time, rather than noting duration of 
activity, which is the accepted unit of measure for endurance. These inconsistencies in 
results do not provide a clear understanding of muscular endurance among BCS. 
Impairments in ROM, strength, and muscular endurance in BCS in the short term 
have been documented.  These impairments likely have an effect on overall UE function 
as self-report functional scores indicate.  The limitation of these data show deficits 
compared to the contralateral limb or to a healthy population in the short term only.  
These deficits may not be long term, but rather due to the necessary healing time required 
following treatment.  Methodological considerations, inconsistencies in results, and the 
lack of comparison of BCS to a healthy population provide rationale for further 
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investigation of muscular endurance among this population. For a portion of BCS, 
motion, strength, and muscular endurance impairments may persist long term, resulting in 
compromised UE function past the first year following BC treatment. 
UE Function 12 months or More after BC Treatment 
The prevalence of UE limitations more than one year after treatment has been 
estimated to be 5-60%.17,73   The incidence of UE limitations is estimated from 10-64% in 
a population of BCS 12 months or more from treatment.74 The complaints reported by 
BCS include pain, lymphedema, and UE functional decline. 
Self-report of function assessment among long term BCS reveals a continued 
perception that the involved UE is functionally impaired.  In a 2 year follow-up of 181 
BCS, self-reported function remained impaired as measured by the Shoulder Disability 
Questionnaire.12 Self-report of function using the DASH also indicates a continued 
perception of functional limitations among long term BCS.  One study documented 
moderate disability utilizing DASH scores in participants 2-67 months following 
treatment, with a mean score of 32.18  Others have documented that over 25% of BCS 6 
years after treatment report DASH scores greater than 20.17  Comparisons of self-report 
of function between BCS more than 1 year from diagnosis and treatment and a healthy 
population have not been reported in the literature. Taken together the studies suggest 
that BCS perceive that treatment for BC results in continued UE functional disability 
beyond the first year after treatment. 
Deficits in motion, strength and muscular endurance of the UE have been 
documented more than 5 years following treatment for BC, although the prevalence of 
deficits declines from the short term.6,10,12,17,20  Range of motion deficits persisted in more 
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than 34% of BCS 5 years after diagnosis,20 with the amount of loss exceeding 25° flexion 
and abduction motion in 24-38% of BCS 2-4 years after surgery.12,75  Strength deficits are 
often self-reported, but in a study of 131 BCS one year following BC surgery, an 8% loss 
in shoulder abduction strength measured by hand-held dynamometry was documented 
compared to pre-operative status,10 and in another study of 75 women with a mean time 
since surgery of 15 months, strength losses ranged from 7-18% for shoulder elevation 
measures.8   
In examining the literature related to muscular endurance among long term BCS, 
less is known.  One study examined an endurance using a test of completing a shoulder 
press task at 90% of 1 repetition maximum (1RM) until failure.  The number of 
repetitions completed by each limb was compared, and no statistical differences between 
the involved and non-involved sides were reported.16     Another study conducted at 18 
months following BC surgery examined upper body strength and endurance, documented 
that 40% of survivors continued to demonstrate deficits comparing involved to non-
involved limbs.15  Whether differences between limbs existed prior to treatment, or are 
less than levels seen in a population of healthy women, cannot be determined.  In total, 
these losses in motion, strength, and muscular endurance can have an impact on function 
in a portion of long term BCS. 
Although functional deficits which occur immediately following treatment for BC 
appear to persist longer than the normal time required for tissue healing, it has not been 
clearly established.  The need for a study examining self-reported and objective measures 
of UE function among long term BCS in comparison to healthy control is needed to 
understand the extent of problems.  
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Conclusion 
 Clinical tools to evaluate UE function include validated self-report scales as well 
as objective measures to quantify impairment.  The most commonly used self-report UE 
functional scale for BCS is the DASH, with good reliability and validity.39,43,44  The 
extensive use of the DASH in both the BC population and other pathological populations 
provides an opportunity to develop an understanding of the extent of functional impact of 
BC treatment.  This information can then be used by the clinical community to guide 
rehabilitation efforts as well as provide a means of prospective surveillance for potential 
dysfunction. 
 Objective clinical measures of UE function have become more precise and 
accurate.  The use of inclinometry to measure ROM improves accuracy, while HHD 
more clearly identifies strength values through objective measures not available with 
MMT.  Clinical measures of muscular endurance remain one area in which better 
assessment tools must be developed.  Although the FIT-HaNSA demonstrates good 
psychometric properties, the test is time consuming to apply clinically.  The UBSE as a 
muscular endurance test lacks psychometric validation at this time.  Better clinical tools 
to measure muscular endurance will provide the rehabilitation community with improved 
methods to identify functional status and take necessary steps to address any deficits. 
 Using these clinical assessments of UE function is an important aspect of 
identifying BCS for whom surgical and adjuvant treatment has resulted in impairments of 
UE function.  Approximately one-third of BCS have persistent losses in ROM and 
strength more than one year after treatment.17  These deficits often impair overall UE 
abilities.74  By measuring ROM, strength, and muscular endurance, and combining these 
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findings with self-report of function, the clinician can developed a focused rehabilitation 
program aimed at a return of function. 
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CHAPTER THREE  
 This chapter describes typical upper extremity functional performance among a 
population of healthy women ages 30-69.  The experimental design, including participant 
selection, dependent measures, data collection procedures and analysis, results, and 
discussion of findings, are presented here. The data from this study will help establish 
how these measures change over the decades, and be used in future comparison to 
women treated for breast cancer. 
Introduction 
 Adequate motion, strength, and muscular endurance of the upper extremity (UE) 
are required to complete functional tasks.  These parameters of UE function are detailed 
in the International Classification of Functioning, Disability, and Health (ICF) within the 
body function domain and are important to understand health within a context of 
function.7   Successful performance of activities of daily living has been shown to 
correlate with range motion of the shoulder76,77  and is dependent upon adequate strength.  
Sustaining functional activity over a period of time requires muscular endurance.  The 
level of UE functional ability is typically measured with self-report and through objective 
measures of motion, strength, and muscular endurance.  Following injury or pathology, 
an understanding of typical levels of self-reported function and objective measures of 
range of motion (ROM), strength, and muscular endurance is needed to be able to 
clinically address deficits in any of these areas with the goal of full return to function. 
Typical values of UE functional self-report, ROM, strength, and muscular 
endurance throughout the adult lifespan have not been consistently documented in the 
literature, and when such reports are available, conflicting information emerges.  Self-
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report of function using the Disabilities of the Arm, Shoulder and Hand (DASH) shows a 
decline in function with increasing age in a sample of 716 individuals,46 but these 
declines are not specific to gender. Declines in motion and strength with increasing age 
have been reported by several researchers,62,63,78-82 but a clear picture of the age at which 
decline begins and whether it is correlated with changes in function, is lacking.  Changes 
in muscular endurance with aging have been minimally studied; one study reported that 
muscular endurance was greater in an older population cohort than a younger one,83 but 
the methodology used, isokinetic measures, is not readily available clinically.  A clear 
picture of the evolving changes in UE function over time needs to be defined. 
Whether and to what extent long term deficits in objective measures of shoulder 
motion, strength, and muscular endurance among BCS are different than those seen in 
normal aging is not clear.  By providing typical values of function throughout the adult 
lifespan, comparisons between a pathological population and a healthy cohort can be 
made.  The primary aim of this study is to collect data to describe UE motion, strength 
and muscular endurance in a healthy female population aged 30-69.  The primary 
hypothesis is that as women age, there will be declines in all areas:  ROM, strength, and 
muscular endurance.  A secondary aim is to examine the effect of dominance on 
objective measures of UE function.  Specifically, it is expected that the dominant 
extremity will have less available motion, and greater strength and muscular endurance 
than the non-dominant extremity. 
25 
 
 
Methods 
Subjects 
A sample of convenience of 79 healthy women (age 49± 11years) agreed to participate in 
this study.  To be included in this study, participants had to be between the ages of 30 and 
69, and report no history of breast cancer. Participants were excluded if they had recent 
(6 month) history of shoulder, cervical or thoracic spine pathology diagnosed by a 
physician, or a history of shoulder, cervical or thoracic surgery.  All participants read and 
signed an approved consent form prior to starting the study. The consent form was 
approved by the Institutional Review Boards of the University of Kentucky, Lexington, 
Kentucky, the University of Dayton and Miami Valley Hospital, Dayton, Ohio.  
Participants were stratified into decades, 30-39, 40-49, 50-59, 60-69, with 20 participants 
per decade except the 60-69 group, which had 19.  The 4 groups did not significantly 
differ in body mass index (BMI) (p=.18) or activity level measured by the International 
Physical Activity Questionnaire (IPAQ) (p=.85).   
Procedures 
Each participant came one time to the clinical laboratory for data collection. 
Measurements were taken by three investigators trained in landmark identification for 
ROM measures, use of a hand-held dynamometer for strength assessment, and in 
administering the Functional Impairment Test – Hand and Neck, Shoulder, Arm (FIT-
HaNSA). The FIT-HaNSA demonstrates good-excellent reliability,24 and ranges from 
.89-.99.28,29 
Participants completed all self-report forms prior to other components of the 
testing.  Demographic variables of age and arm dominance were recorded, and height in 
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meters and weight in kilograms to the nearest tenth were measured and recorded to 
calculate BMI.  
Dependent Variables 
Self-Report Scales 
Activity level was measured using the 7-item International Physical Activity 
Questionnaire (IPAQ), which has good test-retest reliability (r= .70-.90).84  Quality of life 
was measured using the Functional Assessment of Cancer Therapy – Breast (FACT-B), 
which has good construct validity (r=.90) and test-retest reliability (ICC=.88).33  This 
scale is comprised of 27 core questions making up the FACT-G (General cancer quality 
of life scale), plus 9 additional items specific to breast cancer.  Scores range from 0 to 
144; higher values indicate a higher quality of life. Self-reported UE function was 
measured using the Upper Extremity Functional Index (UEFI), a 20 item questionnaire 
with score ranging from 0 to 100, 100 indicating the highest level of function,38 and the 
DASH,35 a 30 item disability scale scored 0 to 100, with lower scores denoting less 
disability.  Both measures have been found to be reliable and valid tools in the evaluation 
of UE function.38-40   
Objective Clinical Measures: 
Range of Motion:  Bilateral active ROM of shoulder flexion, hand behind back 
(HBB), and external rotation (ER) were measured by taking a photograph of the 
participant completing the motion.  ImageJ software (National Institutes of Health, 
Washington DC) was employed to calculate measurements. This method of measuring 
ROM was chosen because multiple investigators were utilized for data collection, and 
initial pilot testing with digital inclinometry produced unacceptable inter-rater reliability 
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levels.  Inter-rater reliability of landmark identification for ROM was established with 
further pilot testing and interclass correlation coefficients (ICC) ranged from .90- .99.  
The ICC for intra-rater reliability of digital measurement of ROM with ImageJ was 
consistently >.95, with a standard error of measurement of less than 2°.    
Landmark identification was completed prior to photographing of the motion.  For 
shoulder flexion, two dots were placed along the midshaft of the humerus aligned with 
the greater tuberosity and lateral epicondyle of the humerus, and two additional dots were 
placed along the midline of the thorax.85  Active shoulder flexion was measured by 
instructing the participant to elevate her arm as high as possible in forward flexion. To 
form the shoulder flexion angle, a line was drawn bisecting the two points demarking the 
midshaft of the humerus, and another was drawn bisecting the two points of the 
midthorax line; the angle in degrees of the intersection of the two lines was measured.85   
(Figure 3.1)    
For HBB, a marker was placed at C7, an easily and reliably palpated structure.86   
The HBB measurement was taken by having the participant reach her hand as high up the 
back as possible while standing; a 10cm reference was in the same plane as the 
participant.  This reference line is necessary to provide a spatial scale of the image so that 
measurement results are in calibrated units, and addresses the issue of perspective.87 
Using ImageJ software, the reference distance was measured to set the scale of 
measurement, and then the distance in centimeters from the C7 spinous process to the 
spinous process in line with the tip of the thumb was recorded; a lower value indicates 
greater motion.27   
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For ER, a dot was placed at the olecranon process and another at the ulnar styloid 
process.85   Active shoulder ER was measured with the participant lying supine with the 
shoulder abducted and elbow flexed to 90° with the elbow resting on two towels to 
approximate the plane of the scapula. The participant was instructed to externally rotate 
her arm as far as possible.  The ER angle was formed by a line drawn through the shaft of 
the ulna and a line perpendicular to the plinth. (See Figure 3.3)  Two trials for each 
motion and each extremity were recorded, and the mean of these values was calculated. 
  
          
Figure 3.1:  Flexion ROM 
Arc of motion generated for illustrative 
purposes only by Kinovea.org 
Figure 3.2:  Hand Behind Back
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Figure 3.3:  External Rotation ROM 
Arc of motion generated for illustrative  
purposes only by Kinovea.org 
Strength:  The strength of the shoulder flexors, internal and external rotators was 
measured by hand-held dynamometry (Lafayette Manual Muscle Test System, Lafayette 
Instruments, Lafayette, IN).  An inelastic 2” wide nylon strap was placed around the 
participant’s wrist for each motion to provide a consistent, immovable resistance for the 
hand-held dynamometer.  Each participant was instructed to generate force to a maximal 
level over 5 seconds in each direction of testing.7,63   Two submaximal practice trials 
were completed prior to testing, followed by 3 trials with 10 seconds rest in between. The 
average of the 3 trials was used for later statistical analysis.54 Shoulder flexion was 
measured with the participant seated, arm elevated to 90°.51 (Figure 3.4) To measure IR 
and ER, the participant’s upper arm was supported on two towels while lying supine with 
the arm at 90° of abduction and 90°elbow flexion.51 In pilot testing , the ICCs for inter-
rater reliability for strength measures ranged from .78-.80, and the standard error of 
measurement was consistently below 1.2%.  (Figures 3.5-3.6) Strength was normalized to 
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body weight and is presented as a percentage of body weight (kg of force/body weight in 
kg). 
  
Figure 3.4:  Flexion Strength
 
Figure 3.5:  Internal Rotation Strength
 
Figure 3.6:  External Rotation Strength
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Muscular Endurance: Upper extremity muscular endurance was measured by using the 
FIT-HaNSA sub-tests 2 and 3 following a previously established protocol for 
performance and termination of testing.29  (Figures 3.7 and 3.8). The FIT-HaNSA 
demonstrates good-excellent test-retest reliability (ICC=.79-.97), and moderate 
concurrent validity (r=.71-.76) with self-reported UE functional scales.28,29 
 
        
Figure 3.7:  FIT-HaNSA sub-test 2          Figure 3.8:  FIT-HaNSA sub-test 3 
 
Statistical Analysis 
   Data were analyzed using IBM SPSS Statistics 19 (New York, NY).  Descriptive 
statistics were calculated for all dependent variables. An independent samples t-test was 
used to analyze BMI.  Mann Whitney U was used to examine activity level (IPAQ), and 
self-reported QOL (FACT-B) and function (DASH and UEFI), as these values were not 
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normally distributed.  A repeated measures analysis of variance (ANOVA) with one 
within factor (limb) and one between factor (group) was used to analyze all measures of 
motion, strength, and muscular endurance with the exception of the FIT-HaNSA sub-test 
3 as this is a bilateral test. There were 2 levels of limb (dominant, non-dominant) and 4 
levels of decades (30-39, 40-49, 50-59, 60-69). Significance was set at p ≤.05. If a 
significant difference was found, a Tukey’s post hoc analysis was performed to identify 
differences with significance set at p≤.05.  The FIT-HaNSA sub-test 3 was analyzed with 
ANOVA, and Tukey’s post hoc testing was performed if the ANOVA was significant at 
p≤.05.   
Results 
Descriptive analyses with means and standard deviations of all variables are 
found in Tables 1-4.  The three self-report scales (FACT-B, DASH, UEFI) were not 
different between the 4 age groups (p value ranges .16-.59). (Table 3.1) There was no 
significant interaction between group by dominance for any measure of motion, strength, 
or endurance. Age was found to have a significant main effect on flexion ROM (p=.01). 
Tukey’s post hoc analysis identified that 60 year olds (148° ± 8) have less flexion motion 
than 30 year olds (159° ± 10) across sides (p=.01).   For all other objective measures of 
ROM, strength, and muscular endurance, no significant differences were found between 
ages (p value ranges .07-.95).  
When examining the influence of limb dominance on ROM, there was 
significantly less motion for the HBB motion on the dominant side (16.4cm±4.3) 
compared to the non-dominant side (13.2cm±4.2) (p<.001); no other differences were 
observed for flexion or external rotation (Table 3.2).  The dominant limb (9.6%±3.1) was 
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stronger than the non-dominant limb (9.0%±3.1) only in flexion (p=.001); no other 
differences were found for measures of strength (Table 3.3). The dominant limb 
(271sec±54) was observed to have greater endurance than the non-dominant limb 
(266sec±63) while performing the FIT-HaNSA sub-test 2 (p=.03) (Table 3.4).   
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Table 3.1:  Means (standard deviation) for Self-report Measures 
Decade FACT-B Total DASH UEFI 
30 (n=20) 124.8 (15) 2.71 (7.2) 98.88 (2.1) 
40 (n=20) 123.4 (16) 3.03 (5.2) 99.12 (1.6) 
50 (n=20) 123.0 (24) 2.55 (3.7) 97.84 (4.0) 
60 (n=19) 127.2 (45) 4.23 ( 4.7) 97.36 (3.4) 
Total (n=79) 124.6 (27) 3.12 (5.3) 98.32 (2.9) 
Abbreviations:  FACT-B:  Functional Assessment of Cancer Therapy – Breast; DASH: Disabilities of the 
Arm, Shoulder and Hand; UEFI: Upper Extremity Functional Index 
 
Table 3.2:  Means (standard deviation) Active Range of Motion  
 Flexion Hand Behind Back External Rotation 
Decade Dominant Non-dominant Dominant Non-dominant Dominant 
Non-
dominant 
30 (n=20) 159 (10°) 157 (10°) 14.5 (3.3cm) 13 (3.5 cm) 93 (10°) 93 (11°) 
40 (n=20) 154 (9°) 156 (10°) 18.2 (5.0cm) 13.1 (5.3 cm) 95 (11°) 95 (7°) 
50 (n=20) 155 (9°) 154 (8°) 15.5 (2.8cm) 13.1 (3.2 cm) 93 (8°) 92 (6°) 
60 (n=19) 148 (8°) 150 (8°) 17.2 (4.9cm) 13.7 (4.6 cm) 97 (9°) 95 (8°) 
Total (n=79) 154 (8°) 155 (9°) 16.4 (4.3cm) 13.2 (4.2 cm) 95 (10°) 94 (8°) 
 
 
Table 3.3:  Means (standard deviation) Strength (% of body weight) 
 Flexion Internal Rotation External Rotation 
Decade Dominant Non-dominant Dominant Non-dominant Dominant Non-dominant 
40 (n=20) 10.4 (3) 9.8 (3) 16.0 (.5) 15.2 (.4) 14.9 (3) 14.6 (4) 
50 (n=20) 9.3 (3) 8.3 (3) 13.9 (.4) 13.8 (.4) 14.3 (5) 14.7 (5) 
60 (n=19) 8.2 (3) 8.1 (3) 13.1 (.4) 13.5 (.5) 13.9 (5) 13.7 (5) 
Total (n=79) 9.6 (3.1) 9.0 (3.1) 14.5 (4.4) 14.2 (4.3) 14.4 (4.4) 14.5 (4.7) 
 
 
Table 3.4:  Means (standard deviation) Endurance (seconds) 
 FIT-HaNSA sub-test 2 FIT-HaNSA 
sub-test 3 Decade Dominant Non-dominant 
30 (n=20) 275 (48) 276 (47) 286 (32) 
40 (n=20) 285 (48) 280 (49) 288 (31) 
50 (n=20) 262 (62) 257 (81) 278 (55) 
60 (n=19) 262 (60) 250 (70) 277 (48) 
Total (n=79) 271(54) 266(63) 282(42) 
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Discussion 
The primary aim of this study was to describe and determine if differences occur with 
aging in self-reported measures of QOL and UE function, and ROM, strength, and 
muscular endurance among healthy women ages 30-69.  The hypothesis that these 
measures would decrease with increasing age was not met for 10 of 11 variables. These 
findings suggest that in general, the level of ROM, strength, and muscular endurance do 
not change in women between the ages of 30 through 69, and future comparisons 
between women with UE pathology to a group of healthy controls, age does not need to 
be considered.  The secondary hypothesis, that the dominant limb would show less 
motion, and greater strength and endurance than the non-dominant limb, was met for 3 of 
7 measures.  Dominance does play a role in some measurements of ROM, strength, and 
endurance, and therefore, limb to limb comparisons should not be relied upon to provide 
accurate comparisons. 
Self-Report Scales 
 Quality of life as reported using the FACT-B was consistently high in this 
population.  No studies have reported mean scores on the FACT-B in a healthy 
population however, in a study of over 1000 healthy individuals, the mean score on the 
FACT-G was 80.88    Calculating the FACT-G scores from this study sample, the range is 
87-91, comparable to previously reported research.88  The overall high scores seen in this 
sample population suggest that QOL does not diminish with age.  It should be noted 
however, that the FACT-B is specific to women treated for BC, and many questions on 
the scale would not apply to an individual without BC.  Although the scale can be scored 
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with skipped questions, it is possible that the results cannot truly measure QOL among a 
population who has not had an experience with BC. 
Self-reported arm function using the DASH and UEFI showed no significant 
functional decline across the four decades.  Mean DASH scores in this study, ranging 
from 2.55 – 4.23, are somewhat lower to those reported in other research.45,46 These 
findings indicate that the sample in this study is without UE functional disability. UEFI 
scores exceeded 97 for all age groups.  No published data are available for UEFI in a 
healthy population, but 2 studies in a pathological population report a mean and standard 
deviation far lower (43.2±17.738 and 65.2±17.989) which would indicate that the 
participants in this study are likely representative of a healthy sample.  Overall, the 
sample of women in this study presented with little to no perceived level of upper 
extremity disability and a high level of self-reported function. 
The Impact of Age on ROM, Strength, and Muscular Endurance 
Only shoulder flexion ROM decreased with increasing age, while age showed no 
effect on all other dependent measures. These findings are consistent with other research 
on the impact of age on ROM changes, with no changes noted in a study of 90 women 
under the age of 60,81 and a decline in flexion motion noted between 2 groups of women 
aged 50-69 and over 70.90 The findings in this study suggest that the decline in shoulder 
flexion ROM may occur in latter decades. Furthermore, the mean values for active ROM 
for shoulder flexion (148°-159°) in this study are consistent with other studies using 
goniometry.78,79  Our use of digital photography and software to measure precise angles 
resulted in high reliability and low measurement error, but is essentially the same process 
as traditional goniometric measurement.   
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A minimum of 120° of shoulder flexion is required to complete UE functional 
tasks such as hair care, bathing, feeding, and most reaching tasks, 76,91  and 148° is the 
threshold required to reach high shelves.92  All mean flexion values in this study were 
148° or greater.  These values indicate that in this sample women appear to retain the 
flexion motion necessary to complete even higher level UE functional tasks.  Trends 
toward declining flexion motion over time have been suggested by other 
researchers,78,81,90 and these changes may impact function. Younger participants in this 
study showed greater flexion values, providing them with approximately 15-20% reserve 
capacity in motion should any shoulder pathology result in a decline in flexion motion, 
while older participants have less reserve capacity available before ROM loss impacts 
function.  Awareness of this trend is important to consider when presenting with an UE 
pathology. 
Although data are not available on typical HBB distance among a healthy 
population, the mean value of the HBB measure in this study indicates greater mobility 
than is seen in pathological populations;26,49 no study has previously examined change in 
HBB with aging.   Comparison of the HBB to other studies investigating IR ROM is 
difficult as the measures are not identical.  Internal rotation measured using HBB is 
commonly used clinically and mimics functional tasks such as donning/doffing a bra or 
tucking in a shirt.  We selected this method to improve reliability of our measure as 
stabilizing the scapula for pure glenohumeral internal rotation was found to be difficult 
between multiple examiners. It should be understood that measuring the distance from C7 
to the tip of the thumb represents more than shoulder internal rotation; it also incorporates 
shoulder extension and scapular mobility,49 yet remains a useful functional description of 
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shoulder motion, and is considered a more accurate measure than identifying vertebral 
level of hand placement.27  As the minimum distance of the HBB measure required to 
complete functional tasks has not been established, it is difficult to identify at which point 
a lack of motion might interfere with UE function.  The clinician, then, should combine 
the measurement with functional abilities questions to determine whether a lack of 
motion is impacting function. 
The mean values of ER ROM (92°-97°) of this study sample are consistent with 
other research,78,79 but literature is inconsistent in terms of increases or decreases with 
rotation motion over time.79,90  Minimum values of ER motion to complete functional 
tasks such as placing items on shelves, hair care, and opening doors require no more than 
approximately 60°.91  All participants demonstrated ER in excess of 90°, indicating no 
functional loss of ROM is present in this sample.  Furthermore, mean values in this study 
suggest that healthy women ages 30-69 possess a significant buffer of 30% of ER ROM 
should future pathology limit this motion.  In this study, no change in ER was seen with 
aging, suggesting that everyday UE use is sufficient to retain functional ranges. 
 Age did not impact any strength measurements of participants in this study.  The 
mean flexion and rotational strength values in this study were lower by approximately 
20-50% than those reported by other researchers using hand-held dynamometry,62,63 
however, conflicting results may be attributed to a difference in methodologies.  The 
dynamometer placement for shoulder flexion in one study was just proximal to the 
humeral epicondyles 62 rather than more distally at the ulnar styloid process as in our 
study.  This change of position shortens the lever arm and subsequently increases force 
production.  The rotation measures were taken at 45° of abduction 63 rather 90° as in our 
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study.  Again, a change in the amount of abduction can change force production.  No 
research has detailed minimum strength measures to complete functional tasks.  When 
examining our strength levels in light of UE function, since participants in this study 
reported minimal disability or functional decline, it can be construed that the strength 
measures obtained are adequate to complete most functional tasks. 
 Muscular endurance does not appear to change across the decades from ages 30 to 
69.  The mean endurance times for sub-tests 2 and 3 of the FIT-HaNSA in this study are 
in agreement with previous literature in a healthy population.28,29  Furthermore, it is 
interesting to note that in the current study the mean age is 20 years greater than in these 
published studies. This suggests muscular endurance appears to remain stable with 
increasing age.  As participants in this study reported no significant functional 
limitations, the mean values reported here indicate this healthy sample has adequate 
endurance to complete functional tasks. 
The Impact of Dominance on Motion, Strength, and Muscular Endurance 
The results of this study show that dominance impacts certain motions, but not all.  
The HBB motion was found to be significantly less for the dominant arm, and although 
some researchers did not find that dominance had an effect on HBB ROM,79,81 others 
have substantiated this difference.78,90,93  Diminished IR ROM on the dominant limb has 
been documented in literature related to throwing athletes, and this decline has been 
attributed to an increase in humeral retroversion, as well as muscular changes resulting 
from the demands on the limb.94  In gathering data on the participants in this study, we 
only examined current activity level but did not investigate what specific activities in 
which these individuals participated presently or in the past.  It is possible that the 
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decreased HBB measure on the dominant limb may be related to similar physiological 
changes seen in throwing athletes based on activity participation. Whether less HBB 
motion on the dominant extremity impacts functional tasks is unclear, however since the 
self-report of function scores do not indicate any functional deficit, it could be concluded 
that the difference is not clinically important. 
Dominance appears to affect strength only for the shoulder flexion measurement 
in this study.  Other researchers have found that dominance had an effect on both flexion 
and rotation strength measures,62,82 while the rotation strength measurements in this study 
were similar for both dominant and non-dominant limbs.  The flexion strength difference 
between limbs in this study is not likely clinically significant as the difference is small 
(less than 1% of body weight), and self-report scores do not indicate functional deficits. 
Muscular endurance does appear to be affected by dominance.  For sub-test 2 of 
the FIT-HaNSA, participants had significantly greater endurance on the dominant limb 
when compared to the non-dominant limb.  To our knowledge, this is the first study 
examining the impact of dominance on muscular endurance using the FIT-HaNSA in a 
healthy population.  This dominance effect conflicts with a study of 20 healthy 
participants (male and female) who completed a unique test of muscular endurance on 2 
separate occasions.95  On the first test session, the non-dominant limb showed greater 
endurance, but on the second session, the durations were equal.95  This retest increase in 
endurance was attributed to effects of motor learning.95 Further investigation of muscular 
endurance of the UE will need to occur to determine the impact of dominance, but the 
findings of this study suggest that dominance must be considered when measuring 
muscular endurance of the upper extremities. 
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Limitations and Future Research 
 This current study had several limitations.  By choosing to measure IR ROM by 
using the HBB measure, we were not measuring pure IR motion, limiting our ability to 
compare our findings with other research, and our ability to determine whether 
differences were due to any particular motion.  Limited information is available on 
typical values of HBB in a healthy population, and we lacked data on specific physical 
activities in which participants engaged, limiting our ability to determine whether sport or 
activity impacted the HBB measure.  The HBB measure, however, remains a functional 
measure of ability to reach behind the back and is a clinically relevant concern of most 
patients with upper extremity disorders. 
 The use of hand-held dynamometry quantifies muscular strength and can be 
performed easily in the clinic, where manual muscle testing remains subjective.  
However, the method to stabilize the hand-held dynamometer is important for accurate 
measurement.58,59  We attempted to minimize this issue by using a resistant nylon strap 
and the clinician as the stabilizing force however, it is possible that inaccurate measures 
were taken resulting in the lack of differences between limbs observed.  
 Future research should focus on reliable, valid, and clinically feasible methods to 
measure UE strength with a hand-held dynamometer.  Muscular endurance measures 
across ages needs to be established, and differences based on dominance need to be 
further explored.  Furthermore, the link between objective clinical measures and self-
report of function needs to be identified. 
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Conclusion 
 The findings in this study show that only flexion motion declines with aging, 
however, does appear to remain within functional ranges.  The decline in the 60+ age 
range, however, leaves less reserve capacity for loss of motion due to pathology.  
Strength and muscular endurance appear to remain stable throughout the ages assessed in 
this study.  Dominance plays a role in motion, strength, and muscular endurance.   These 
limb-to-limb differences need to be considered in clinical evaluations. It is often a 
convenient comparison to measure to the contralateral side using the assumption that 
limbs are symmetrical, but it appears that in an otherwise healthy population there are 
some measures that are asymmetrical. Comparisons to typical values or normative data 
may provide a more accurate assessment of these objective measures of shoulder function 
than limb to limb comparisons typically done in the clinic. 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Mary Insana Fisher 2013  
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CHAPTER FOUR 
The focus of this chapter is the comparison of upper extremity function between 
survivors of breast cancer (BCS) and a population of healthy women, using in part data 
derived from the first study (Chapter 3).  Additionally, the differences between the 
involved and non-involved limbs of BCS, considering whether the involved limb is the 
dominant limb, will be investigated.  Typical levels of self-reported quality of life (QOL) 
and arm function, and values of shoulder range of motion (ROM), strength, and muscular 
endurance of BCS will be presented.  Differences between BCS and controls, and 
involved/non-involved limbs are discussed, and the need for more responsive measures of 
muscular endurance are presented. 
Introduction 
 Functional performance of the upper extremity (UE) includes adequate levels of 
ROM, strength, and muscular endurance, defined both through the International 
Classification of Functioning, Disability, and Health (ICF) and the ICF Core Set for 
breast cancer (BC).7,13  Persistent complaints of UE functional deficits in long term BCS 
have been documented,6,70,73,96-98 but the extent of these deficits and whether they can be 
attributed to BC treatment or normal aging has not been adequately examined.  
Specifically, 21% of long term BCS report a decline in UE function measured on the 
Disabilities of the Arm, Shoulder and Hand (DASH) scale up to 6 years following 
diagnosis.17  A 10% decline in ROM has been reported more than 5 years following 
treatment for BC.18  Strength declines of 10-15% are reported 1-5 years after 
treatment.8,18  These studies have examined UE function in relation to self-report and the 
contralateral limb, but have not made a direct comparison to a group of healthy women.  
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These deficits may actually be a result of changes seen with normal aging.  It is important 
for direct comparison of measures of UE function between BCS and healthy women to 
determine whether existing deficits are due to BC treatment or normal aging.  
Muscular endurance, the ability to sustain an activity over time and a necessary 
component of UE function,7 has been minimally examined in the BC population.  In a 
study using 90% of 1 repetition maximum (1RM) weight in a repetition to failure 
activity, no significant differences between involved and non-involved limbs were 
found,16 however, using 90% of 1RM may bias strength rather than endurance muscle 
fibers.  A unique test of upper body strength and endurance (UBSE)14 was used in 2 
studies. At 6 months, a 20% deficit in the involved limb of BCS was documented, which 
declined to 10% but persisted at 18 months.14,15 These inconsistent findings and limited 
data on muscular endurance in long term BCS warrants the need for further investigation 
into UE muscular endurance as a component of UE function. 
Subjective self-reported function and objective ROM, strength, and muscular 
endurance measures of BCS in comparison to a healthy cohort need to be examined in 
order to identify whether the potential deficits are due to BC interventions or to the 
normal aging process. The purpose of this study is to determine the extent of UE 
functional deficits in BCS compared to a population of healthy controls.  We hypothesize 
that BCS will have lower levels of self-reported QOL and UE function, and ROM, 
strength, and muscular endurance compared to women without a history of BC.  A 
secondary aim is to examine differences between the involved and non-involved limb of 
BCS who are at least 12 months post treatment, also considering dominance.  We 
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hypothesize that the involved limb will have less motion, strength and endurance 
compared to the non-involved limb in BCS.   
Methods 
Subjects: A sample of convenience of 50 BCS agreed to participate in this study.  To be 
included in this study, participants had to be between the ages of 30 and 69, and have 
received at least one of the following BC treatments:  mastectomy, axillary lymph node 
dissection (ALND), axillary radiation.  All treatments had to be completed 12 months or 
more from the date of testing.  Participants were excluded if they had recent (6 month) 
history of shoulder, cervical or thoracic spine pathology diagnosed by a physician, or a 
history of shoulder, cervical or thoracic surgery.  All participants read and signed an 
approved consent form prior to starting the study. The consent form was approved by the 
Institutional Review Boards of the University of Kentucky, Lexington, Kentucky, the 
University of Dayton and Miami Valley Hospital, Dayton, Ohio.  One participant with 
breast cancer was excluded after screening revealed she had undergone rotator cuff 
surgery on her involved side prior to the cancer diagnosis.  Two other BCS were 
excluded after clarification that the radiation received was local to the tumor site and not 
the axilla. Additionally, 5 BCS had been diagnosed with bilateral BC, and were excluded 
as limb to limb comparisons could not be made.  Forty-two BCS are included in the final 
analyses.  Data from the initial study describing typical values of UE function among 
women without breast cancer (Chapter 3) were used for comparison.  Women who had 
not had breast cancer ages 30-39 were excluded from final analysis for comparison as no 
breast cancer survivors in the same age range were recruited with a resulting 59 women 
without breast cancer.   
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Procedures:  Each participant came one time to the clinical laboratory for data collection. 
Measurements were taken by three investigators trained in landmark identification for 
ROM measures, use of a hand-held dynamometer for strength assessment, and in 
administering the Functional Impairment Test – Hand and Neck, Shoulder, Arm (FIT-
HaNSA).  The FIT-HaNSA demonstrates good-excellent reliability,24 and ranges from 
.89-.99.28,29  
Participants completed all self-report forms prior to other components of the 
testing.  Demographic variables of age and arm dominance were recorded, and height in 
meters and weight in kilograms to the nearest tenth were measured and recorded to 
determine BMI.  
Dependent Variables 
Self-Report Scales 
Activity level was measured the 7-item International Physical Activity Questionnaire 
(IPAQ), which has good test-retest reliability (Spearman correlation coefficients .70-
.90).84  Quality of life was measured using the Functional Assessment of Cancer Therapy 
– Breast (FACT-B), which has good construct validity (r=.90) and test-retest reliability 
(ICC=.88).33  This scale is comprised of 27 questions making up the FACT-G (General 
cancer quality of life scale) plus 9 additional items specific to breast cancer for a score of 
ranging from 0 to144; higher values indicate a higher quality of life. Self-report of UE 
function was measured by the Upper Extremity Functional Index (UEFI), a 20 item 
questionnaire with score ranging from 0 to 100, 100 indicating the highest level of 
function,38 and the DASH, a 30 item disability scale scored 0 to 100, with lower scores 
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denoting less disability.  Both measures have been found to be reliable and valid tools in 
the evaluation of UE function.38-40   
Objective Clinical Measures: 
Range of Motion:  Bilateral active ROM of shoulder flexion, hand behind back 
(HBB), and external rotation (ER) were measured by taking a photograph of the 
participant completing the motion.  ImageJ software (National Institutes of Health, 
Washington DC) was employed to calculate measurements. This method of measuring 
ROM was chosen because multiple investigators were utilized for data collection, and 
initial pilot testing with digital inclinometry produced unacceptable inter-rater reliability 
levels.  Inter-rater reliability of landmark identification for ROM was established with 
further pilot testing and interclass correlation coefficients (ICC) ranged from .90- .99.  
The ICC for intra-rater reliability of digital measurement of ROM with ImageJ was 
consistently >.95, with a standard error of measurement of less than 2°.    
Landmark identification was completed prior to photographing of the motion.  For 
shoulder flexion, two dots were placed along the midshaft of the humerus aligned with 
the greater tuberosity and lateral epicondyle of the humerus, and two additional dots were 
placed along the midline of the thorax.85  Active shoulder flexion was measured by 
instructing the participant to elevate her arm as high as possible in forward flexion. To 
form the shoulder flexion angle, a line was drawn bisecting the two points demarking the 
midshaft of the humerus, and another was drawn bisecting the two points of the 
midthorax line; the angle in degrees of the intersection of the two lines was measured.85       
For HBB, a marker was placed at C7, an easily and reliably palpated structure.86   
The HBB measurement was taken by having the participant reach her hand as high up the 
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back as possible while standing; a 10cm reference was in the same plane as the 
participant.  This reference line is necessary to provide a spatial scale of the image so that 
measurement results are in calibrated units, and addresses the issue of perspective.87 
Using ImageJ software, the reference distance was measured to set the scale of 
measurement, and then the distance in centimeters from the C7 spinous process to the 
spinous process in line with the tip of the thumb was recorded; a lower value indicates 
greater motion.27    
For ER, a dot was placed at the olecranon process and another at the ulnar styloid 
process.85  Active shoulder ER was measured with the participant lying supine with the 
shoulder abducted and elbow flexed to 90° with the elbow resting on two towels to 
approximate the plane of the scapula. The participant was instructed to externally rotate 
her arm as far as possible.  The ER angle was formed by a line drawn through the shaft of 
the ulna and a line perpendicular to the plinth. Two trials for each motion and each 
extremity were recorded, and the mean of these values was calculated. 
Strength:  The strength of the shoulder flexors, internal and external rotators was 
measured by hand-held dynamometry (Lafayette Manual Muscle Test System, Lafayette 
Instruments, Lafayette, IN).  An inelastic 2” wide nylon strap was placed around the 
participant’s wrist for each motion to provide a consistent, immovable resistance for the 
hand-held dynamometer.  Each participant was instructed to generate force to a maximal 
level over 5 seconds in each direction of testing.7,63   Two submaximal practice trials 
were completed prior to testing, followed by 3 trials with 10 seconds rest in between. The 
average of the 3 trials was used for later statistical analysis.54 Shoulder flexion was 
measured with the participant seated, arm elevated to 90°.51  To measure IR and ER, the 
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participant’s upper arm was supported on two towels while lying supine with the arm at 
90° of abduction and 90°elbow flexion.51 In pilot testing, the ICCs for inter-rater 
reliability for strength measures ranged from .78-.80, and the standard error of 
measurement was consistently below 1.2%.  Strength was normalized to body weight and 
is presented as a percentage of body weight (kg of force/body weight in kg). 
Muscular Endurance: Upper extremity muscular endurance was measured by 
using the FIT-HaNSA sub-tests 2 and 3 following a previously established protocol for 
performance and termination of testing.29  The FIT-HaNSA demonstrates good-excellent 
test-retest reliability (ICC=.79-.97), and moderate concurrent validity (r=.71-.76) with 
self-reported UE functional scales.28,29  
Statistical Analysis 
   Data were analyzed using IBM SPSS Statistics 19 (New York, NY).  Descriptive 
statistics were calculated for all variables of self-reported QOL and function, ROM, 
strength, and muscular endurance for each group.  To confirm that the characteristics of 
each group were similar, independent samples t-tests were used to analyze age, BMI and 
activity level.    
Whether the dominant or the non-dominant limb was the involved limb in BCS 
had to be considered prior to data analysis.  This is based on findings from previous 
research in Chapter 3 which show that dominance has an effect on at least one measure in 
ROM, strength, unilateral muscular endurance tasks.  Therefore, the BCS group was 
subdivided into two groups: involved dominant or involved non-dominant. The level of 
complexity of comparisons resulted in multiple analyses being conducted.  (Figures 4.1-
4.2)  Significance for all analyses was set a priori at p≤.05.   
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Figure 4.1a:  Statistical Analyses for Between Group Comparisons; All 3 Groups  
 BCS Involved Dominant 
BCS Involved Non-dominant 
Control 
Post hoc Tukey 
MANOVA 
ANOVA ANOVA 
Self-Report 
of Function 
Quality of Life 
FACT-B  
Which Measure 
DASH 
UEFI 
 Endurance FIT-HaNSA 
Subtest 3 
Group Determination 
•BCS Involved Dominant 
• BCS Involved Non-dominant 
• Control 
Post hoc Tukey 
Group Determination 
• BCS Involved Dominant 
• BCS Involved Non-dominant 
• Control 
BCS = Breast Cancer Survivor 
ANOVA = Analysis of variance 
MANOVA = Multivariate analysis of variance 
ROM = Range of motion 
FACT-B = Functional Assessment of Cancer Therapy – Breast 
FIT-HaNSA = Functional Impairment Test – Hand and Neck, Shoulder, Arm 
DASH = Disabilities of the Arm, Shoulder, Hand 
UEFI = Upper Extremity Functional Index 
HBB = Hand Behind Back ROM 
IR = Internal Rotation Strength 
ER = External Rotation 
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Figure 4.1b:  Statistical Analyses for Between Group Comparisons;  
Limb to limb Comparisons 
  
 BCS Involved Dominant                     Control Dominant 
BCS Involved Non-dominant            Control Non-dominant 
ANOVA 
Which Measure 
Flexion 
HBB/IR 
 
ANOVA 
 Endurance FIT-HaNSA 
Subtest 2 
MANOVA 
Strength ROM 
BCS = Breast Cancer Survivor 
ANOVA = Analysis of variance 
MANOVA = Multivariate analysis of variance 
ROM = Range of motion 
FACT-B = Functional Assessment of Cancer Therapy – Breast 
FIT-HaNSA = Functional Impairment Test – Hand and Neck, Shoulder, Arm 
DASH = Disabilities of the Arm, Shoulder, Hand 
UEFI = Upper Extremity Functional Index 
HBB = Hand Behind Back ROM 
IR = Internal Rotation Strength 
ER = External Rotation 
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Figure 4.2:  Comparison of Involved to Non-involved Limbs of BCS  
 BCS Involved Dominant                      BCS Non-involved Non-dominant  
BCS Involved Non-dominant                                BCS Non-Involved Dominant 
ANOVA 
Which Measure 
Flexion 
HBB/IR 
 
 Endurance FIT-HaNSA 
Subtest 2 
Strength ROM 
ANOVA 
MANOVA 
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Comparison between the BCS and Control Group 
We first analyzed the FACT-B scores and sub-test 3 of the FIT-HaNSA, (a 
bilateral task) using two separate ANOVAs, with three groups: BCS involved dominant, 
BCS involved non-dominant, and control group.  If significance was found, post hoc 
testing with Tukey’s was used to determine for which group significance was found. 
Direct comparisons of the involved limb of BCS to the respective limb of the 
control group were necessary for the FIT-HaNSA sub-test 2, a unilateral endurance task. 
Two separate ANOVAs were performed comparing BCS involved dominant limb to the 
dominant limb of the control group, and BCS involved non-dominant limb to the non-
dominant limb of the control group.  With only 2 groups being compared, no post hoc 
testing was necessary. 
To compare differences in self-report of function between the BCS and control 
group, a MANOVA was used because the comparison involved two related measures 
(UEFI and DASH), and three groups (BCS involved dominant, BCS involved non-
dominant, and control). If significance was found, a subsequent ANOVA was performed 
to determine which measure was involved.  Significant differences on the ANOVA were 
analyzed post hoc with Tukey’s to determine for which group significant differences 
existed.   
The dependent variables ROM and strength each had 3 measures (flexion, 
HBB/IR, ER) on 2 limbs (dominant and non-dominant); therefore results could be 
related.  Consequently, the MANOVA model was used assessing these potential 
relationships. Four separate MANOVAs were used to compare the involved limb of BCS 
to the respective limb of the control group: ROM dominant, ROM non-dominant, 
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strength dominant, and strength non-dominant.  Direct comparisons were made between 
the involved dominant limb of BCS to the dominant limb of control group, and the 
involved non-dominant limb of the BCS to the non-dominant limb of the control group. 
In the presence of a significant difference in these variables, ANOVAs were carried out 
to determine for which specific variable differences existed.  As only 2 groups were 
involved, either BCS involved dominant and the dominant limb of controls, or BCS 
involved non-dominant and the non-dominant limb of controls, no post hoc testing was 
needed. 
Figure 4.1 details the analyses performed comparing BCS to the control group. 
BCS Involved to Non-involved Comparison 
 Because dominance may impact some dependent measures, the BCS group 
subdivisions were maintained:  involved dominant and involved non-dominant.  To 
compare involved and non-involved limb in BCS, the change score of the involved limb 
minus the non-involved limb was calculated for all measures of ROM, strength, and 
muscular endurance (FIT-HaNSA sub-test 2, only). The affected limb, dominant or non-
dominant, was considered as a fixed factor in comparisons.  Significance was set a priori 
at p≤.05 for all analyses.  Figure 4.2 details these analyses. 
 The ANOVA model was used to compare the change score on sub-test 2 of the 
FIT-HaNSA.  Two separate MANOVAs were used to compare ROM and strength 
variables.  In the presence of a significant difference in these variables, ANOVAs were 
carried out to determine for which specific variable differences existed.  No post hoc 
testing was necessary for 2 group comparisons. 
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Results 
Participant demographics of age (p=.50), body mass index (p=.53) and activity levels 
were similar. (Table 4.1) Among BCS, the mean duration since surgical treatment was 69 
months (range 12-241); 31 underwent a mastectomy, 20 underwent ALND, and 13 had 
axillary radiation.  Of these, 11 BCS had both a mastectomy and ALND, and 6 underwent 
all three procedures. 
Comparison Between the BCS and Control Group 
Quality of life measured by the FACT-B was statistically significantly lower 
among BCS compared to the control group (p=.040).  (Table 4.2)  Post hoc testing 
showed that this was the case for women whose BC was on the non-dominant limb 
(p=.050), with mean values for BCS (108±17.4) lower compared to the control group 
(124.7±30.7).   
The MANOVA was significant for self-report functional measures (p<.001), with 
the subsequent ANOVA showing both UEFI and the DASH were significant at p<.001.  
Post hoc testing revealed BCS report lower levels of UE function and higher levels of UE 
disability than the control group, regardless of whether the involved limb was on the 
dominant or non-dominant side. (Table 4.2) 
For ROM measures comparing the involved limb of BCS to the respective limb of 
controls, MANOVAs were significant for both dominant and non-dominant ROM. For 
dominant limb ROM, both flexion (p=.01) and ER (p=.03) ROM were less in the BCS 
group than the control group. When the non-dominant limb was the involved limb, all 3 
ROM measures, flexion (p=.001), HBB (p=.01), and ER (p=.01) ROM were less in the 
BCS group compared to the control group. (Table 4.3) 
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Strength measures were significantly lower in BCS only when the non-dominant 
limb was the involved limb. Non-dominant IR (p=.004) and ER (p=.004) strength were 
less among BCS when compared to the control group. (Table 4.4) 
Muscular endurance measured by the FIT-HaNSA was not different between BCS 
and the control group. The mean of control group and BCS for sub-test 2 on the dominant 
limb was 270±57sec and 248±84sec, respectively (p=.18), and for the non-dominant 
limb, the mean for the control group was 263±68sec, and BCS 244±70sec (p=.30).  The 
mean of the control group for sub-test 3 was 281±45sec, and for BCS it was 271±61sec 
(p=.61).  
BCS Involved to Non-involved Comparison 
  MANOVA results of the involved to non-involved limb were statistically 
significant different for ROM only (p<.001); all other dependent variables were not 
significantly different for strength measures (p=.35), and sub-test 2 on the FIT-HaNSA 
(p=.07).  Subsequent ANOVA testing on ROM revealed that HBB and ER were 
significantly different between the involved and non-involved sides.  In examining the 
specific direction of differences, these findings indicate that the dominant limb had on 
average 3 cm less HBB motion than the non-dominant limb, regardless of BC 
involvement (p<.01).  Similar results were observed for ER ROM (p=.03).  In those 
women who had BC on their dominant side, ER was 4° greater than on the non-involved 
non-dominant side.  Among BCS with BC on the involved non-dominant side, dominant 
ER was 5° greater on the dominant non-involved side.  Dominant ER ROM was greater 
regardless of which side BC occurred. 
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Table 4.1:  Baseline Characteristics (mean (SD)) 
 Age, years BMI IPAQ (mets) 
Control (n=59) 54 (8) 26.8 (5.4) 3190 (2926) 
BCS (n=42) 56 (8) 27.9 (6.3) 3260 (4056) 
Abbreviations: BMI = Body Mass Index; IPAQ = International Physical Activity Questionnaire 
 
 
 
Table 4.2:  Self-Report Scores (mean (SD)) 
 FACT-B UEFI DASH 
Control (n=59) 124.7 (30.7) 98.1 (3.2) 3.3 (4.6) 
BCS Involved Dominant (n=23) 114 (16.2) 91.2 (9.7) 11.5 (11.3) 
BCS Involved Non Dominant (n=19) 108 (17.4) 89.9 (11.7) 10.3 (13.4) 
Abbreviations:  FACT-B = Functional Assessment of Cancer Therapy, Breast; UEFI = Upper 
Extremity Functional Index; DASH = Disabilities of the Arm, Shoulder, Hand 
 
Table 4.3:  Range of Motion (mean (SD)) 
 Flexion Hand Behind Back External Rotation 
 Dominant Non-dominant Dominant Non-dominant Dominant Non-dominant 
Control 152°(9) 153°(9) 17cm (4.5) 13.5cm (4) 95°(9) 94°(7) 
BCS 146°(13) 142°(18) 18cm (5.6) 16.9cm (6.4) 89°(11) 87°(14) 
Control n = 59, BCS Involved Dominant n = 23, BCS Involved Non-dominant n = 19.   
For BCS, all motions are on the involved limb only.   
 
 
Table 4.4:  Strength (% Body Weight) (mean (SD)) 
 Flexion Internal Rotation External Rotation 
 Dominant Non-dominant Dominant Non-dominant Dominant Non-dominant 
Control 9.3 (3) 8.7 (3) 14.3 (4.5) 14.2 (4.2) 14.3 (4.2) 14.3 (4.4) 
BCS 8.3 (2.6) 7.6 (2.7) 12.9 (4.5) 11 (3.5) 14.6 (5.8) 10.8 (4.7) 
Control n = 59, BCS Involved Dominant n = 23, BCS Involved Non-dominant n = 19.   
For BCS, all strength measures are on the involved limb only.   
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Discussion 
This study compared self-reported QOL and UE function levels, and objective 
measures of function limited to shoulder ROM, strength, and muscular endurance in BCS 
and healthy controls. This study was unique in that it directly compared BCS to a group 
of healthy women, considering limb dominance.  These comparisons have been 
minimally investigated among long term BCS. We hypothesized that BCS would have 
lower levels of self-reported QOL and UE function, and objective measures of motion, 
strength, and muscular endurance than a sample of women without BC, which was true 
for most but not all variables.  Women treated for BC report lower QOL levels, lower UE 
function and higher disability, and demonstrate less overall UE ROM, and less IR and ER 
strength, than a sample of women without breast cancer.  We expected that long term 
BCS would have lower objective measures of ROM, strength, and muscular endurance on 
the involved limb compared to the non-involved limb but this was not found to be true in 
this sample. Range of motion results indicated differences were due to arm dominance, 
rather than the impact of BC treatments. 
Comparison Between the BCS and Control Groups 
Among women whose BC occurred on the non-dominant limb, statistically lower 
values of QOL were reported compared to the control group, suggesting that this 
subgroup of BCS may have more difficulty returning to a level of QOL similar to healthy 
counterparts.  Only one study examined the impact of the whether the cancer occurred on 
the dominant or non-dominant side on QOL, and in a study of 59 BCS with lymphedema, 
QOL was not associated with side of cancer.99 The sample population in this current 
study did not have lymphedema, perhaps accounting for a difference in findings.  Yet, 
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when examining the levels of QOL and objective measures of function among BCS, 
those with cancer on the non-dominant limb not only have lower QOL levels, but also 
consistently demonstrate statistically significantly lower ROM and strength than a sample 
of healthy women.   These findings may indicate that in this sub-population of BCS, 
return of function and QOL may not reach the same levels as when cancer occurs on the 
dominant limb, perhaps because the non-dominant limb is not used as frequently. The 
effects of dominance on QOL need further investigation. 
Self-report of UE function on both the DASH and UEFI were statistically 
significantly lower among BCS compared to levels reported by a healthy sample, 
however the values are not clinically significant.  Although the mean values of the DASH 
for BCS in this study were similar to a study of 53 BCS who underwent a mastectomy at 
least 12 months prior to measurement (range: 10.12 ±9.39 - 12.97 ±11.6),100 they are 
lower compared to reports of BCS 6 months after treatment whose mean DASH score 
was 19.4 ±17,9 suggesting that there is a perceived return of function occurring over time.  
In evaluating our results in comparison to those of a general population, BCS report 
similar levels of function.  The mean DASH score of a general population sample of 1706 
adults was 10.1±14.7,45 and among 327 healthy women age 18-65 was 14.3±14.9.46  The 
mean score on the DASH among BCS 6 years after treatment in this study are 
approximating these cited values, and indicate that recovery of function to normal ranges 
can occur with adequate time. 
Nearly all ROM measures in BCS were impaired by 5-10% compared to a healthy 
sample even at 6 years post-treatment.  Only the HBB measure on the dominant involved 
side was not significantly diminished, and even in a healthy population, there appears to 
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be limited IR motion on the dominant side compared to the non-dominant side.94  The 
mean shoulder flexion motion among BCS in this study is 11-15° less than that reported 
among BCS within the first 6 months after treatment,9 suggesting that shoulder flexion 
ROM loss may continue past one year. Although none of the motions declined to what is 
generally accepted as clinically significant level, a minimum range of 148° of shoulder 
flexion is necessary for reaching a high shelf.92  A secondary analysis of BCS with 
motion less than 148° revealed that 25 of 42 (60%) participants of this sample did not 
have this level of motion available on the involved limb, and 9 of the 25 (36%) reported 
moderate to severe difficulty in reaching an overhead shelf on their DASH self-report 
form. A Chi square analysis however, revealed no significant relationship between loss of 
motion and self-report (p=.08).  The HBB and external rotation motions, although 
statistically significantly less among BCS, would not be considered to be clinically 
deficient.  All functional UE tasks can be completed with minimal to no difficulty at the 
measured HBB and ER ROM levels.  Overall, although ROM is significantly less among 
BCS in this study, the values are not clinically relevant, with only a portion of the sample 
demonstrating a limitation in one specific functional task.  BCS at 6 years following 
treatment generally demonstrate ROM at a level similar to their healthly counterparts.   
Loss of strength was found to primarily affect BCS who had cancer on their non-
dominant side.  Strength impairments in IR and ER show a 23-25% deficit compared to a 
population of women without a history of BC.   Additionally, the values of IR and ER 
strength of BCS in this study are more than 30% less than published reference values for 
a healthy population of similar aged females.62,63  Although methodologies for 
measurement differed slightly (flexion resistance at the epicondyle instead of distally at 
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the ulnar styloid process,62 and rotation positioning at 45° abduction instead of 90° 
abduction62,63), the deficits appear greater than expected through differing methodologies.  
Whether these deficits can be definitively linked to a decline in UE function is less clear, 
as minimum strength values for completing tasks are difficult to define. As DASH scores 
were within normal ranges, that most strength measures among BCS in this study appear 
to not be impaired.  Overall, BCS demonstrate levels similar to those of women without 
breast cancer. 
BCS Involved to Non-involved Comparison 
Our hypothesis that ROM, strength and muscular endurance in the involved limb 
would be less than the non-involved limb was not supported.  Although both rotation 
motion measures, HBB and ER ROM, were statistically significantly different, the results 
showed that dominance was the effect rather than whether the limb underwent BC 
treatment.  Dominant limbs had less HBB motion and greater ER ROM than non-
dominant limbs regardless of cancer status, a finding in agreement with other research 
examining the effect of dominance on shoulder rotation motion.93  Muscular endurance 
appeared to recover to levels of the non-involved limb in this sample of BCS 6 years 
following treatment, and these findings are in agreement with a study of 40 BCS 
approximately 2 years after treatment who demonstrated similar levels of endurance on 
the involved and non-involved limbs.16 
It appears that over time, BCS regain motion, strength, and muscular endurance to 
similar levels of the non-involved limb.  In previous work among a healthy cohort of 
women, dominance impacted the HBB measure, flexion strength, and muscular 
endurance measured on sub-test 2 of the FIT-HaNSA (see Chapter 3).  The cohort of 
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BCS did not have greater flexion strength and muscular endurance on their dominant 
limb. This could suggest that when BC occurs on the dominant side, the recovery may 
not be complete.  Because there are no significant limb-limb differences in BCS as would 
be expected, when cancer occurs on the non-dominant side, our results suggest a decline 
occurs in these measures on the non-involved dominant limb.  These findings can be 
explained in part by a recent study examining three-dimensional shoulder kinematics and 
EMG muscle activity among a group of 155 BCS with unilateral cancer approximately 3 
years after treatment (47 participants underwent mastectomy, and 48 axillary lymph node 
dissection and/or axillary radiation).101  The BCS were compared to 21 age-matched 
healthy women.  The authors concluded that all kinematic parameters were abnormal and 
EMG output was less among BCS compared to healthy counterparts.101 That both the 
involved and non-involved limbs in this study differed from a healthy cohort but not from 
each other substantiate that the BC treatment effects can extend into the non-involved 
limb.  These findings support the need to make clinical comparisons of motion and 
strength beyond the non-involved side but should be evaluated against a healthy 
population to better assess the level of dysfunction.  
The Importance of Muscular Endurance Assessment 
Research on muscular endurance among BCS is in the early stages. Two 
published studies that have examined this aspect of UE function have used a test which 
does not yet have established reliability and validity, yet has shown a decline in 
endurance compared to the non-involved limb.14,15  The current study is the first study to 
examine the use of the FIT-HaNSA in a population of BCS.  Although the findings in this 
study show that UE endurance is not impaired compared to a similar healthy population, 
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the mean scores on sub-test 2 and 3 of the FIT-HaNSA among all the participants in this 
study compare similarly to a study of 17 younger (mean age 32) individuals with 
shoulder pathology.29  This would suggest there are some deficits in endurance but that 
they appear to be an aging effect not a result of the breast cancer. It is also possible that 
no differences between groups were found because this test demonstrated a low level of 
responsiveness with large variances among groups.  Furthermore, a large ceiling effect 
was observed in performing the FIT-HaNSA. Sixty-six to eighty-one percent of the 
control group completed the full test duration of 300 seconds and 53-76% of BCS 
completed the full test.  Examining muscular endurance with a more responsive test 
might provide a clearer picture of the level of muscular endurance among BCS. 
Limitations 
Several limitations in this study may have impacted the results.  No information 
about whether the BCS in this study had previous rehabilitation was collected.  It is 
possible that this group had interventions directed toward UE functional return.  The 
range of time after BC treatment was long (12-271 months).  This lengthy time period 
may allow normal tissue healing to occur.  A longitudinal study analyzing at what point 
in time after treatment BCS symptoms improve may give insight into the probable 
timeline for return of function.  The variance associated with the FIT-HaNSA was large 
(>60 seconds), indicating that this measure was not as responsive in identifying those 
with decreased endurance as is preferred.  Furthermore, the significant ceiling effect of 
greater than 50% of all participants finishing the complete test does not allow for 
discrimination between levels of muscular endurance. 
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 Identifying why women who have BC on their non-dominant limb have greater 
long term deficits need to be accomplished.  Determining why BCS seem to have a 
carryover loss in function on their non-involved limb is also important to investigate and 
focus rehabilitation efforts. Better clinical measures of muscular endurance, those which 
are less variable in responsiveness and without a significant ceiling effect, need to be 
investigated.  Together, answering these questions can guide early rehabilitation to 
prevent long term problems. 
Conclusion 
The findings in this study suggest that the self-reported level of QOL and UE 
function among BCS is lower than women without BC even at 6 years following 
treatment.  The primary objective limitations were lower ROM measures among BCS 
than a control group.  This loss of motion may have potential implications on functional 
tasks.  The differences between BCS and a control population on self-report scales, 
combined with objective measures of UE function, indicate a lower level of UE function 
among long term BCS.  An interesting yet unexpected finding was the effect dominance 
plays in BCS UE function. Those found to have BC affecting their non-dominant side 
appear to have more persistent ROM and strength deficits compared to BCS affecting 
their dominant side. 
 
 
 
 
 
Copyright © Mary Insana Fisher 2013 
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CHAPTER FIVE 
A modification of a clinical test used to measure upper body strength and endurance is 
presented in this chapter.  The experimental design, including participant selection, 
dependent measures, data collection procedures and analysis, results, and discussion of 
findings, are presented here. The modified Upper Body Strength and Endurance test will 
be used to examine muscular endurance in healthy women and women who have been 
treated for breast cancer.  The new test will be compared to the Functional Impairment 
Test – Hand and Neck, Shoulder, and Arm, to determine whether it is a more responsive 
and therefore better clinical tool to measure UE muscular endurance. 
Introduction 
Muscular endurance is an essential component of upper extremity (UE) abilities, 
and is one component of UE function within the body structure and function domains of 
the International Classification of Functioning, Disability and Health (ICF).7  Few 
options exist for the clinician to measure UE muscular endurance, and as a result, it is not 
often tested. Options include using an isokinetic testing device, the Functional 
Impairment Test – Hand and Neck, Shoulder, and Arm (FIT-HaNSA),29 or the Upper 
Body Strength and Endurance Test (UBSE).14  
Clinically feasible measures of muscular endurance must be easy to perform, take 
a reasonably short amount of time to complete, and require minimal specialized 
equipment. Furthermore, these tests should demonstrate sound psychometric properties 
including reliability, validity, and responsiveness.  Responsiveness is defined as the 
ability to measure important difference between groups.102 Isokinetic testing, which has 
good psychometric features, can be time intensive and requires expensive equipment. The 
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FIT-HaNSA has demonstrated good reliability (ICC=.79-.97)28,29 and convergent 
validity(r=.76),28 in research focusing on rotator cuff and shoulder impingement 
pathology.28,29 Testing requires an adjustable shelving unit and up to 15 minutes of time 
to test one limb.  The FIT-HaNSA has not been used to our knowledge  in published 
research for BCS, however, previous research (Chapter 4) suggests that there is a large 
ceiling effect for BCS.  This ceiling effect indicates the test may not be demanding 
enough. Large variances were present as well, indicating a lower level of responsiveness.  
The UBSE was introduced to capture the strength and muscular endurance in BCS.14,15 
This test is easy to perform, requires minimal equipment, but can be time consuming; the 
total test time varies based on and individual’s fatigue level, but with several stages, can 
take over 15 minutes.  Data on the psychometric properties of the UBSE are not available 
from the literature.   
A responsive, easy to execute, and reliable test of UE muscular endurance is 
needed to assess this component of UE function.  The purpose of this study is to compare 
muscular endurance among BCS who completed treatment a minimum of 12 months 
earlier, to matched controls.  The hypothesis is that BCS will demonstrate lower levels of 
muscular endurance than a group of women without BC.  A secondary purpose is to 
investigate a modification of the Upper Body Strength and Endurance test (mUBSE) for 
clinical use in the measurement of muscular endurance.  It is expected that the mUBSE 
will be less variable compared to the FIT-HaNSA, and demonstrate a greater challenge to 
muscular endurance. 
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Methods 
Subjects  
A sample of convenience of 18 BCS and 18 matched participants without BC agreed to 
participate in this study.  To be included in this study, participants had to be between the 
ages of 40 and 69; BCS had to have received at least one of the following BC treatments 
at least 12 months prior to data collection:  mastectomy, axillary lymph node dissection 
(ALND), axillary radiation.  Participants were excluded if they had recent (6 month) 
history of shoulder, cervical or thoracic spine pathology diagnosed by a physician, or a 
history of shoulder, cervical or thoracic surgery.  Participants were matched on age and 
body mass index (BMI). All participants read and signed a consent form approved by the 
Institutional Review Board of the University of Dayton, Dayton, Ohio, prior to starting 
the study.  One BCS and one control participant were removed from analysis as no 
participants who matched on age and BMI were recruited. 
Procedure 
Each participant came one time to the clinical laboratory for data collection. After 
consent was signed, demographic variables of age and arm dominance were recorded, 
and height in meters and weight in kilograms to the nearest tenth were measured and 
recorded to determine BMI. Heart rate was taken for a baseline measure; this was 
repeated before and after each endurance test.  Each participant then completed a 5 
minute warm-up on the treadmill, with 1 pound wrist weights.  Participants were 
instructed to walk at a comfortable pace and swing their arms to include UE muscular 
warm-up.   
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Following warm-up, the participant was instructed in testing procedures, including 
maximal voluntary isometric contraction (MVIC) testing using a hand-held 
dynamometer. Strength testing was performed at 6 different time points during the 
testing.  At each time point, 3 trials of MVIC were recorded and averaged.  The first 2 
testing trials were utilized for familiarization and baseline assessment.  The trial which 
had the greatest mean and had less than a 10% coefficient of variance was then used for 
comparison of later strength testing for muscle recovery.  The second trial was used as 
baseline 65% of the time. 
Estimated 1 repetition maximum (1RM), a submaximal repetition test, was used 
to determine a 1RM value.  Each participant was given a heavy load, and the number of 
repetitions correctly performed was counted.  The estimation is based on the following 
formula where x is the number of repetitions completed:23 
Estimated 1RM = weight lifted/(1.0278-.0278x) 
Endurance testing was randomized such that either the FIT-HaNSA or the 
mUBSE was completed first.  After completing each endurance test, the participant was 
asked to rate her level exertion using the Borg CR-10.103  A 25 minute minimum rest 
break was given between the endurance testing procedures to allow for muscle 
recovery.104  During this time, participants completed 5 self-report questionnaires.  After 
25 minutes, a brief warm-up of the UE was completed prior to the final endurance test.  
To be able to begin endurance testing, the strength measurement had to reflect a value of 
at least 90% of baseline to ensure that muscle recovery had occurred.104 If the participant 
could not achieve this 90% level, additional rest and/or warm-up was provided, until the 
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90% level could be reached.  Heart rate was taken, and if it had not returned to baseline, 
further rest was also provided. 
In a pilot study of 5 healthy females, data on 10 limbs was collected to assess test-
retest reliability.  MVIC strength testing and the mUBSE demonstrated acceptable 
reliability, ICC=.76 and .75 respectively.   
 
 
Figure 5.1:  Data Collection Procedure  
70 
 
 
Dependent Variables 
Self-report Scales 
Activity level was measured using the 7-item International Physical Activity 
Questionnaire (IPAQ), which has good test-retest reliability (r= .70-.90).84 Quality of life 
was measured using the Functional Assessment of Cancer Therapy – Breast (FACT-B), 
which has good construct validity (r=.90) and test-retest reliability (ICC=.88).33  This 
scale is comprised of 27 questions making up the FACT-G (General cancer quality of life 
scale) plus 9 additional items specific to breast cancer for a score of ranging from 0 
to144; higher values indicate a higher quality of life. Self-reported UE disability was 
assessed with the Disabilities of the Arm, Shoulder, and Hand (DASH), a reliable and 
valid39,40 30 question disability scored 0-100, with lower scores indicating less disability.  
The Piper Fatigue Scale, a reliable and valid scale frequently used in the cancer 
population to assess levels of fatigue resulting from treatment, has 22 scaled questions 
related to levels of fatigue.105-107  The scale is scored 0-10, with lower scores indicating 
lower fatigue.106  The Physical Activity Assessment Inventory (PAAI) is a new scale 
intended to assess levels of self-efficacy in relation to physical activity among BCS, 
scored 0-100 with higher scores indicating higher self-efficacy levels.108  Preliminary 
research has shown this scale to be reliable (Cronbach’s alpha=.95).108   
Objective Clinical Measures: 
Perceived Exertion: Perceived exertion was measured using the BORG CR-10, a 1-10 
scale with higher scores indicating more perceived exertion, with good reliability and 
validity.103 Perceived exertion can indicate how strenuous an activity is.103  The levels of 
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the BORG CR-10 will be compared after each endurance test to provide information 
about the tests. 
Strength:  The strength of the shoulder abduction was measured using hand-held 
dynamometry.  The hand held dynamometer (Lafayette Manual Muscle Test System, 
Lafayette Instruments, Lafayette, IN) was set in a fixed bracket to ensure consistent 
resistance for all participants, with the participant seated, and arm positioned at 90° 
abduction in approximately 30° of the frontal plane.7 (Figure 5.2)  Each participant was 
instructed to generate force to a maximal level over 5 seconds.7,63   Two submaximal 
practice trials were completed prior to testing; 10 seconds rest was given between trials. 
The peak force produced for each trial was recorded, and an average of 3 trials was used 
for analysis.54 Baseline testing included two sessions of 3 trials; the highest average value 
with ≤10% coefficient of variance was used as the baseline strength measure.   
 
Figure 5.2:  Strength Testing Position 
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Endurance 
FIT-HaNSA: Participants completed sub-tests 2 and 3 of the FIT-HaNSA 
following a previously established protocol for performance and termination of testing.29   
The FIT-HaNSA demonstrates good-excellent reliability,24 ranging from .89-.99,28,29 and 
good convergent validity.28   
mUBSE: This endurance test modifies the UBSE14 by removing the stages of 
incremental increase in resistance. In this modified version, the participant uses 50% of 
her 1RM estimated weight for the combination upright row/shoulder press motion.  This 
weight is repeatedly lifting through the motion until failure.   Criteria for stopping the test 
include:  1) Participant can no longer continue lifting weight;  2)  Participant cannot reach 
her maximum high point 2 times consecutively; 3)  Participant cannot maintain cadence 
of lift (2 beats up/2 beats down); and 4)  Participant demonstrates extremely poor form of 
lift.  The number of repetitions completed is recorded.  Each arm is tested separately as 
pilot testing showed that it was difficult for participants to continue on one arm when the 
other fatigued which would limit evaluation of limb differences in the BCS group.  See 
Figures 5.3-5.5. 
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          Figure 5.3: 
Beginning mUBSE 
Figure 5.4: 
         Mid-point mUBSE
            Figure 5.5: 
          Top position mUBSE
 
 
Statistical Analysis 
 An a priori analysis of power was completed on pilot data.  The mean 
(SD) of a control group completing the mUBSE was 19 (4), and for BC was 
14(1).  Conservative values were used to calculate power and effect size, 
increasing the BC mean (SD) to 15(4).  With these values, the power analysis 
conducted at alpha = .05, revealed a true power of 82%; 14 participants per group 
(28 total) would provide an effect size of 1.0. 
 Data were analyzed using IBM SPSS Statistics 19 (New York, NY).  
Descriptive statistics were calculated for all variables of self-report scales, and 
muscular endurance for each group.  To confirm that the characteristics of each 
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group were similar, independent samples t-tests were used to analyze age, BMI 
and activity level.    
Whether the dominant or the non-dominant limb was the involved limb in 
BCS was recorded for data analysis.  This is based on findings from previous 
research in Chapter 3 which show that dominance has an effect on at least one 
measure in ROM, strength, unilateral muscular endurance tasks.  Therefore, the 
BCS group was subdivided into two groups: involved dominant or involved non-
dominant.  Comparisons were then made for like limbs:  involved dominant BCS 
to dominant control, and involved non-dominant to non-dominant control. 
Significance for all analyses was set a priori at p≤.05 
To examine differences between BCS and the control group, analysis of 
variance (ANOVA) models were constructed for the DASH, FACT-B, Piper 
Fatigue Scale, PAAI, and the bilateral muscular endurance test sub-test 3 of the 
FIT-HaNSA.  If significance was found (p≤.05), then Tukey post hoc testing was 
used to determine which group was involved.   To examine differences between 
the BCS and controls for the mUBSE and sub-test 2 of the FIT-HaNSA, we ran 
separate ANOVAs. The involved dominant limb of BCS was compared to the 
dominant limb of controls, and the involved non-dominant limb of the BCS to the 
non-dominant limb of the control group. Because only two groups were 
compared, the involved limb to the respective limb of the control group, no post 
hoc testing was necessary 
The level of responsiveness of mUBSE was compared to the FIT-HaNSA 
by examining the level of variance of each test.  We ran separate ANOVAs 
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comparing the involved limb to the non-involved limb of BCS, and evaluated the 
F-statistic of each endurance test.  Secondary analyses with independent samples 
t-tests included comparison of percent change in MVIC and heart rate levels, and 
the level of perceived exertion using BORG CR-10. 
Results 
Participant characteristics are detailed in Table 5.1.  Participant 
demographics of age and body mass index (BMI) were similar (p>.05).  BCS had 
a significantly greater activity level than the control group (p=.049).  (Table 5.1)  
Among BCS, the mean duration since surgical treatment was 85 months (range 
17-217); 14 underwent a mastectomy, 12 ALND, and 4 had axillary radiation.  Of 
these, 5 BCS had both a mastectomy and ALND, and 3 underwent all three 
procedures. 
Comparison of BCS to the Control Group 
No significant differences were found between BCS and the control group 
on any of the self-report scales (p=.07-.40).  (Table 5.2)  No significant 
differences were found between the BCS and the control group on either the FIT-
HaNSA or the mUBSE (p=.44-.72). (Table 5.3) 
Comparison of the FIT-HaNSA to the mUBSE 
 To compare the levels of variability of the FIT-HaNSA and mUBSE, the 
F-statistic of an ANOVA was evaluated using repeated measures general linear 
models comparing the involved limb to the non-involved limb of BCS.  Both F-
statistics were 2.5.  
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The percent change in MVIC and HR after each endurance test was used 
to evaluate how demanding each test was.  The MVIC and HR after each test was 
subtracted from the pre-test value to calculate the change score.  Only the percent 
change in MVIC for mUBSE on the dominant side resulted in a statistically 
significant difference between groups on the independent samples t-tests. The 
control group (22±14%) had a statistically greater drop in endurance than the 
involved dominant BCS (<1±20%) (p=.01).  The percent change in MVIC on the 
non-dominant mUBSE was not statistically significant between groups. (Table 
5.4)  The percent change in heart rate pre- to post on the mUBSE for BCS 
(29±16%) and controls (30±14%) was not statistically different.  The percent 
change in heart rate pre- to post on the FIT-HaNSA for BCS (27±18%) and 
controls (31±15%) also was not statistically significant.  The BORG CR-10 
perceived exertion levels were also not statistically different for BCS and controls 
on either the mUBSE (9±1 and 8±1, respectively) or the FIT-HaNSA (7±1 and 
8±2, respectively).  
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Table 5.1:  Baseline Characteristics for Group Comparisons 
 Age, years BMI IPAQ (mets) 
Control (n=17) 58 (7) 28.5 (5.5) 2107 (1554) 
BCS (n=17) 58 (7) 28.7 (5.3) 4392(4339) 
Abbreviations: BMI = Body Mass Index; IPAQ (International Physical Activity 
Questionnaire 
 
 
Table 5.2:  Self-Report Scales  
 FACT-B DASH Piper PAAI 
Control (n=17) 103.9 (11.4) 6.0 (5.5) 2.1 (1.4) 74.2 (19.1) 
BCS Inv Dom (n=6) 119.6 (10.3) 9.8 (16.1) 2.6 (1.6) 65.9 (25.6) 
BCS Inv ND (n=11) 107.9 (18.2) 15.7 (16.0) 3.5 (2.2) 62.8 (25.5) 
Abbreviations:  FACT-B=Functional Assessment of Cancer Therapy-Breast; DASH=Disabilities of 
Arm, Shoulder, and Hand; PAAI=Physical Activity Assessment Inventory; BC=breast cancer; Inv 
Dom=Involved Dominant; Inv Non-dom=Involved Non-dominant 
 
 
Table 5.3:  Muscular Endurance  
 mUBSE  FIT-HaNSA sub-test 2 FIT-
HaNSA 
subtest 3 
 Dominant Non-dominant  Dominant Non-dominant 
Control (n=17) 18 (5) 15 (4) 254 (75) 233 (86) 273 (54) 
BCS (n=17) 19 (12) 16 (4) 266 (65) 257 (64) 258 (72) 
BCS Involved Dominant n=6; BCS Involved Non-dominant n=11 
For BCS, all endurance values are on the involved limb, except Fit 3, which is a bilateral 
task.  
mUBSE measured in repetitions; FIT-HaNSA in seconds  
 
 
Table 5.4 Percent Change MVIC pre-post mUBSE and FIT-HaNSA  
 mUBSE FIT-HaNSA  
 Dominant Non-dominant Dominant Non-dominant 
Control (n=17) 22 (14%) 19 (15%) 23 (15%) 17 (19%) 
BCS (n=17) <1 (20%) 16 (9%) 14 (15%) 12 (22%) 
Abbreviations: mUBSE = modified Upper Body Strength and Endurance test; FIT-HaNSA 
= Functional Impairment Test – Hand and Neck, Shoulder, Arm 
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Discussion 
The primary aim in this study, to investigate levels of UE muscular endurance 
between a sample of BCS and a control group, revealed no differences between 
the groups on either measure of muscular endurance.  Analyses of self-report 
measures examining quality of life, UE function, fatigue, and self-efficacy 
regarding physical activity also showed no differences between groups.  The 
findings of this study indicate that BCS 7 years after treatment appear to achieve a 
full return of UE function and endurance. 
Comparison of BCS to the Control Group 
 In examining self-report scales, although no differences were found 
between BCS and the control group, perceptions of quality of life and UE 
function trended toward differences.  BCS in this study reported a higher FACT-B 
score (p=.07), indicating a higher perceived quality of life than the control group.  
The FACT-B is written specifically for BCS with questions unique to a person 
who has had cancer.  It is possible that women who had not had cancer could not 
accurately answer the questions.  Although the scale can be scored with blank 
answers, it may be that too many answers were left blank, making any assessment 
of quality of life among this group inaccurate.  Whether the control group had 
difficulty answering these questions or the number of questions left blank resulted 
in an inaccurate assessment of QOL, the FACT-B may not be interpretable. 
While the DASH scores for BCS were higher than the control group 
(p=.07), these scores are within a range of what could be considered normal 
scores.  Two large studies examining typical DASH scores among a population 
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without UE pathology reported scores between 10.1(14.7)45 - 14.3(14.9).46  
Despite a trend toward a difference indicating a more disability among BCS, the 
findings in this study reveal that recovery of function occurs by 7 years after 
treatment.  
Endurance is one component of UE function, and the findings of this study 
show that women who have had treatment for BC on average 7 years prior 
demonstrate levels of endurance comparable to women without BC.  No studies 
have investigated muscular endurance at this point in the recovery of BCS for 
comparison.  One study examined muscular endurance using the Upper Body 
Strength and Endurance test in 186 BCS 18 months after treatment and reported 
that 40% continued to demonstrate a loss endurance compared to the non-
involved limb.15  Further evidence that BCS recover muscular endurance is that 
the values on the FIT-HaNSA among the BCS in this study were actually higher 
than those of the control group.  The large variance associated with this test may 
have made any differences between groups difficult to appreciate.  Values on the 
FIT-HaNSA among a similar group of 42 BCS were slightly lower than seen in 
this study (see Chapter 4).  These findings may be explained in part by the activity 
level among this sample of BCS.  The BCS reported high levels of activity on the 
IPAQ; a mean score of 4392 mets is categorized as a high activity level.84  
Whether comparing the results of this study to previous work or to the control 
group, BCS appear to have normal levels of muscular endurance. 
 Breast cancer survivors who are, on average, 7 years removed from BC 
treatment, have regained a level of UE function and endurance similar to that of 
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women without a history of BC.  Furthermore, an active lifestyle as reported by 
this sample may mitigate any long range effects on UE endurance. 
Comparison of the FIT-HaNSA to the mUBSE 
 The units of measure and magnitude of results of the FIT-HaNSA and 
mUBSE greatly differ, making direct comparisons of their respective variances 
invalid.  The FIT-HaNSA scores ranged from 92-300 seconds, with standard 
deviations as large as 86, whereas the mUBSE scores ranged from 11-44, with 
standard deviations no greater than 12.   The F-statistic in an ANOVA tests 
whether the variances of two populations are significantly different.24  The F-
statistic was examined for each endurance test using an ANOVA comparing the 
involved limb to the non-involved limb in BCS.  For both the FIT-HaNSA and the 
mUBSE, the F-statistic was 2.5, suggesting that both tests have similar variance.  
Although not statistically significant, it is interesting to note that the mean 
endurance on the involved limb was less than the non-involved on the mUBSE, as 
would be expected, but greater than the non-involved on the FIT-HaNSA.  This 
may suggest that the mUBSE is more accurately assessing the endurance as the 
direction of difference is as expected in the involved limb.  The ceiling effects on 
the FIT-HaNSA remain high, with as many as 71% (12/17) of BCS and 76% 
(13/17) of the control group reaching the full test duration of 300 seconds.  The 
mUBSE without a ceiling effect offers an alternative measure of muscular 
endurance. 
To examine whether one endurance test was a greater physiological 
challenge than the other, the percent change in MVIC and heart rate, and the 
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levels of the BORG CR-10 perceived exertion were examined.  The significant 
finding that the percent change in MVIC for the mUBSE was greater among the 
control group than the BCS may be explained by the presence of highly active 
BCS as indicated by high IPAQ scores; this BCS subgroup had more than twice 
as high of an activity level measured on the IPAQ (5235±4122) compared to the 
controls (2107±1554).  That this percent change of MVIC was the only significant 
finding out of 4 variables examining MVIC change, suggests that both tests 
similarly challenge muscular endurance.  The percent change in heart rate was not 
different between groups for either endurance test, indicating neither test 
challenges the cardiovascular system more than another.  Mean BORG CR-10 
levels were not different, suggesting that each test was equally difficulty.  Both 
tests were perceived as a hard activity.  These findings indicate that the mUBSE is 
not as challenging as the FIT-HaNSA. 
That the mUBSE compared similarly in our study to the FIT-HaNSA, 
which has been more extensively studied in the general shoulder population and 
demonstrates good reliability and validity with self-report scales, suggests that 
this test of muscular endurance may be used in lieu of the FIT-HaNSA.  The test 
takes less than 5 minutes to perform, and because it is a repetition to failure test, 
has no ceiling effects.  These features may make it an attractive alternative to the 
FIT-HaNSA in clinical practice. 
Limitations 
 This study had a limited number of participants, although an a priori 
power analysis of the mUBSE indicated the sample size was adequate.  The long 
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survival period among the BCS of 7 years (range 17-217 months) may have 
allowed full healing to occur.  The BCS in this sample were highly active, 
exceeding the activity level of the control group.  It is possible this group was a 
not a true representation of BCS in term of this activity level. 
 Future research into UE endurance among BCS should focus on more 
immediate post treatment time periods to determine how long deficits persist.  
Continued comparisons to a healthy population need to be made to fully 
appreciate any differences.  Better tests of UE muscular endurance need to be 
investigated. 
Conclusion 
Breast cancer survivors who are 7 years post treatment appear to have 
similar levels of muscular endurance to that of women without a history of BC.  
Furthermore, these women report a level of quality of life and UE function similar 
to healthy women.  Less variable clinical measures of muscular endurance have 
yet to be developed, but the mUBSE presents a possible alternative to the FIT-
HaNSA in testing upper extremity muscular endurance as it takes less time to 
administer and suffers no ceiling effects. 
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CHAPTER SIX 
 Despite research documenting the deficits in upper extremity (UE) 
function in survivors of breast cancer (BCS) post-operatively and beyond the first 
year of treatment, few studies have compared BCS to a sample of healthy controls 
using a battery of functional tests.  The impairments of BCS have not been 
examined in light of any decline which occurs with normal aging.  Whether self-
reported quality of life (QOL) and UE function, range of motion (ROM), strength, 
and muscular endurance deficits in BCS are due to aging or breast cancer (BC) 
treatment has not been fully investigated.  The need to understand the level of 
impairment in long term BCS in comparison to women without BC shoudl be 
established.  The primary purpose of this research was to compare UE function 
among long term BCS and similar aged women without cancer.  We expected that 
BCS who received treatment more than 12 months previously would demonstrate 
less motion, strength, and muscular endurance and higher levels of self-reported 
UE disability as well as lower levels of QOL than similar aged women without 
BC. 
Typical Measures of Upper Extremity Function in Healthy Women 30-69 
In making comparisons between BCS and women without BC, it is 
important to understand whether subjective and objective measures of UE 
function change with age, or vary limb to limb based on dominance.  An 
understanding of perceived QOL among healthy women is also necessary.  We 
undertook to describe QOL and UE function among women without BC ages 30-
69.  We hypothesized that as women aged, there would be declines in all 
84 
 
 
measures, and that the dominant limb would show less ROM, and greater strength 
and muscular endurance than the non-dominant limb.   
In examining UE function among 79 women age 30-69 without BC, 
available UE ROM varied little as women aged, with statistical significance found 
only for dominant flexion ROM between women in their 30’s and women in their 
60’s.  This difference was not clinically relevant however, as the mean flexion 
among 60 year old women, at 148°, is great enough to complete even high level 
UE functional tasks.92  All other motion, strength, and muscular endurance 
variables did not differ across the four decades studied. 
Dominance appears to play a role in ROM and strength measures. The 
hand behind back motion, representing some level of internal rotation ROM, was 
less on the dominant side compared to the non-dominant, and is consistent with 
other research.78,90,93  This, however, was the only motion wherein dominance 
played a role. Shoulder flexion on the dominant side was significantly stronger 
than the non-dominant side, which may have implications for clinical strength 
testing in women with breast cancer. These differences did not impact perceived 
function levels, as self-report functional levels are unimpaired in these women.   
The impact of dominance on muscular endurance of the UE has not been 
extensively studied, but in our study, muscular endurance was greater on the 
dominant limb.   Intuitively, this may be because the dominant limb tends to be 
used to a greater extent in daily activities, and therefore type I endurance muscle 
fibers may be enhanced. 
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A Comparison of Upper Extremity Function Between BCS and Healthy Controls 
Research has suggested that long term BCS demonstrate declines in UE 
function beyond the time required for normal healing,17,73 however, these are 
comparisons to a premorbid status which does not account for change over time, 
or to a contralateral limb, rather than to a population without BC.  The purpose of 
this study was to compare QOL and UE function among women who had been 
treated for breast cancer at least 12 months prior to data collection to a sample of 
healthy women.  It was believed that BCS would show deficits in self-reported 
QOL and UE function, and measures of ROM, strength, and muscular endurance.  
A secondary purpose was to compare ROM, strength, and muscular endurance of 
the involved limb to the non-involved limb of BCS. We believed the involved UE 
would demonstrate lower levels on all measures than the non-involved limb. 
All self-reported measures of QOL and UE function were statistically 
significantly lower among BCS compared to a healthy sample.  Although BCS 
report higher levels of disability than women without BC, the value reported is 
similar to the population at large.45,46  BCS also demonstrated significantly less 
motion than women without BC. However, these differences appear to be 
minimal and may have no clinical relevance as the moderately lower values 
demonstrated by BCS would still allow daily tasks to be completed.  Strength 
deficits appear when the cancer is on the non-dominant limb.  These deficits, 
however, may not clearly impact functional tasks, as DASH scores remained 
within a range of normal.  Muscular endurance did not appear to be affected by 
BC treatment, suggesting that over time, women recover to normal levels.  
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Limb to limb comparisons within the BCS revealed no relevant 
differences related to BC treatment.  Both HBB and ER were significantly less on 
the dominant limb regardless of whether the limb underwent BC treatment.  No 
other differences were found.  These findings may implicate a carry-over effect of 
treatment to the non-involved limb as the population without BC demonstrated 
greater strength and endurance in the dominant limb. Therefore, the fact there is 
no expected difference could indicate an impairment. 
Muscular Endurance Among Women 
Muscular endurance is not easily measured in the clinic due to a lack of 
valid and reliable measures.  The Functional Impairment Test – Hand, and Neck, 
Shoulder, Arm (FIT-HaNSA) demonstrated a high variance, suggesting that the 
level of responsiveness is low, as well as high ceiling effects.  The final study 
examined a new clinical test of UE function. The modified Upper Body Strength 
and Endurance test (mUBSE) was compared to the FIT-HaNSA in both healthy 
controls and BCS in a matched study.  We hypothesized that BCS would 
demonstrate lower levels of UE endurance than matched controls.  Furthermore, 
we hoped to see that this new test would be more responsive than the FIT-
HaNSA.  Results, however, indicated that BCS have nearly the same level of UE 
endurance as women without BC, suggesting that long term BCS recover 
muscular endurance over time.  The mUBSE, although not suffering from ceiling 
effects, did not demonstrate more responsiveness than the FIT-HaNSA.   
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Conclusion 
Overall, BCS 6 years removed from treatment recovered UE function to 
levels similar to a population of women without BC.  Self-reported QOL and UE 
function was lower among BCS than a sample of women who had not had BC but 
remains within the range of normal.  Some deficits in motion and strength are 
present among long term BCS, but are likely not clinically relevant.  Breast 
cancer survivors can recover UE function over time to levels within normal 
ranges. 
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Appendix B 
Consent to Participate in a Research Study  
A comparison of upper extremity motion, strength, endurance, 
function, and quality of life between female breast cancer survivors 
and healthy controls 
WHY ARE YOU BEING INVITED TO TAKE PART IN THIS RESEARCH? 
You are being invited to take part in a research study about arm motion, strength, 
endurance and use in women. You are being invited to take part in this research study 
because you are a female between ages 30 and 69. If you volunteer to take part in this 
study, you will be one of about 200 people to do so.   
 
WHO IS DOING THE STUDY? 
 
The person in charge of this study is Mary Fisher PT, a student of University of Kentucky, 
Department of Rehabilitation Sciences.  She is being guided in this research by Tim Uhl, 
PhD ATC PT.  There may be other people on the research team assisting at different 
times during the study.  
 
WHAT IS THE PURPOSE OF THIS STUDY? 
By doing this study, we hope to learn about the motion, strength, endurance, use of the 
arm and shoulder, and the quality of life among women who have had breast cancer 
treatment and compare that information to women who have not had any history of breast 
cancer or shoulder injury. 
ARE THERE REASONS WHY YOU SHOULD NOT TAKE PART IN THIS STUDY? 
If you are under the age of 30, or older than 69, you may not take part in this study. If you 
are a male you may not participate in the study. If you had shoulder, neck or back 
surgery you may not participate in the study. If you have had an injury to your shoulder, 
neck, or back in the last 6 months you may not participate in this study. If you have had 
breast cancer that has been limited to lumpectomy and/or sentinel lymph node biopsy 
you cannot participate in this study. 
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?  
The research procedures will be conducted at the University of Kentucky Musculoskeletal 
Research Laboratory. This lab is located on the second floor, room 222 of the Charles T. 
Wethington Building connected to the University of Kentucky Clinic at 900 South 
Limestone. You will be asked to come to the Musculoskeletal lab 1-2 times during the 
study.  Each of those visits will take about 90 minutes.  The total amount of time you will 
be asked to volunteer for this study is 3 hours over the next 1-2 weeks. 
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WHAT WILL YOU BE ASKED TO DO? 
You will complete five questionnaires about your general health, your arm use, and how 
you feel.  The investigator will take measurements of your arm motion using devices 
which measure the motion, strength and endurance of your arm. 
Questionnaires: 
You will complete a general medical questionnaire asking you about your health status, 
previous surgeries, and any medications you are taking, to see if you can participate in 
this study.  Two questionnaires will ask you about how you use your arm in daily 
activities.  Another questionnaire will ask you about how you feel in general. The last 
questionnaire will ask you about your overall activity level. 
Range of Motion Measurements: 
Your arm range of motion will be measured on both sides in three directions, elevation, 
inward and outward rotation.  Shoulder elevation will be measured while upright and you 
will be asked to lift your arm up in front of you high a possible. Shoulder inward rotation 
will be measured while you are standing, and you will be asked to place your hand 
behind your back as high up the spine as possible. Shoulder outward rotation will be 
measured while lying on your back with your arm out to the side and your elbow resting 
on two towels. You will rotate your arm toward the floor by your head. A picture will be 
taken of your arm once you have completed each motion.  The angle of motion will be 
measured from this picture.  Once the measurement has been completed, the picture will 
be destroyed. 
Strength Measurements: 
Your arm strength will be measured on both sides in the same directions as your motion.  
A device called a dynamometer will be used to measure your strength and it will be 
attached to your wrist with an inelastic nylon strap. We will place your arm in a position 
and you will push against the strap for 5 seconds as hard as you can. This will be 
repeated twice in all directions on both arms. You will be given a 15 -30 second break 
between maximal efforts to allow for recovery. You will be given two practice trials and 
then we will record the two trials of maximal force you exert in each direction. These 
measures will be taken while seated.  For shoulder elevation, you will lift your arm as you 
did for the range of motion measure.  For the inward and outward rotation strength 
measures, your arm will be at your side and you will rotate toward your stomach or away 
from your stomach.   
Arm Endurance: 
You will be asked to lift a 2 pound weight from eye level down about 10 inches and back 
up as long as you can complete the task, up to 5 minutes with each arm.  Lastly, you will 
be asked to fasten and unfasten bolts in a plate above your head for as long as you can 
complete the task, up to 5 minutes. 
We may request that you be contacted after the study is completed, for further follow-up 
or future research.  If you decline, no further contact with you will be made. 
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WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? 
None of the measurements will be dangerous to you.  You may experience minor side-
effects of muscle soreness  from pushing hard against the force device or stretching your 
muscles.  You may experience minor bruises from pushing hard against the force device.  
These side-effects should resolve within a day.   
Please report any side-effects to the Principal Investigator, Mary Fisher, at 937-238-0633. 
There is always a chance that any medical treatment can harm you, and the 
investigational treatment in this study is no different.  In addition to the risks listed above, 
you may experience a previously unknown risk or side effect. 
WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY? 
There is no guarantee that you will get any benefit from taking part in this study.  Your 
willingness to take part, however, may, in the future, help researchers and clinicians 
better understand and/or treat other breast cancer survivors. You will be provided a copy 
of your results along with a standardized exercise program to help you improve in any 
deficits revealed from testing.  
DO YOU HAVE TO TAKE PART IN THE STUDY? 
If you decide to take part in the study, it should be because you really want to volunteer.  
You will not lose any benefits or rights you would normally have if you choose not to 
volunteer.  You can stop at any time during the study and still keep the benefits and rights 
you had before volunteering.   
IF YOU DON’T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER 
CHOICES? 
If you do not want to be in the study, there are no other choices except not to take part in 
the study. 
WHAT WILL IT COST YOU TO PARTICIPATE? 
The cost to you for participation in this study requires that you travel to and pay parking 
costs for the University of Kentucky Musculoskeletal Lab.  There are no other costs 
associated with your participation. 
WHO WILL SEE THE INFORMATION THAT YOU GIVE? 
We will make every effort to keep private all research records that identify you to the 
extent allowed by law. 
Your information will be combined with information from other people taking part in the 
study. When we write about the study to share it with other researchers, we will write 
about the combined information we have gathered. You will not be personally identified in 
these written materials. We may publish the results of this study; however, we will keep 
your name and other identifying information private. 
We will make every effort to prevent anyone who is not on the research team from 
knowing that you gave us information, or what that information is. First, we will give 
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everyone a code number and remove their names from most documents.  All information 
will be kept in a locked lab on a password protected computer.  The information that we 
obtain from you in this study will be included in a larger database in the Research Lab.  
The information that we obtain from you may be included in future studies for other types 
of comparisons.  However, the information used will have no identifiable link to your 
personal identification. 
This study is being conducted in conjunction with the University of Dayton, and the 
Institutional Review Board at the University of Dayton may request access to the data 
collected at the University of Kentucky for review. 
You should know, however, that there are some circumstances in which we may have to 
show your information to other people. For example, the law may require us to show your 
information to a court or to tell authorities if you report information about a child being 
abused or if you pose a danger to yourself or someone else.  Officials from the University 
of Kentucky may look at or copy pertinent portions of records that identify you. 
CAN YOUR TAKING PART IN THE STUDY END EARLY? 
If you decide to take part in the study you still have the right to decide at any time that 
you no longer want to continue. You will not be treated differently if you decide to stop 
taking part in the study. 
The individuals conducting the study may need to withdraw you from the study.  This may 
occur if you are not able to follow the directions they give you, or if they find that your 
being in the study is more risk than benefit to you.  There are no expected adverse 
effects should you withdraw from this study.  
ARE YOU PARTICIPATING OR CAN YOU PARTICIPATE IN ANOTHER RESEARCH 
STUDY AT THE SAME TIME AS PARTICIPATING IN THIS ONE? 
You may take part in this study if you are currently involved in another research study.  It 
is important to let the investigator/your doctor know if you are in another research study.  
You should also discuss with the investigator before you agree to participate in another 
research study while you are enrolled in this study. 
 
WHAT HAPPENS IF YOU GET HURT OR SICK DURING THE STUDY? 
If you believe you are hurt or if you get sick because of something that is due to the 
study, you should call Mary Fisher at 937-238-0633 immediately.  Mary Fisher will 
determine what type of treatment, if any, that is best for you at that time. 
It is important for you to understand that the University of Kentucky does not have funds 
set aside to pay for the cost of any care or treatment that might be necessary because 
you get hurt or sick while taking part in this study. Also, the University of Kentucky will not 
pay for any wages you may lose if you are harmed by this study.   
The medical costs related to your care and treatment because of research related harm 
will be your responsibility but may be paid by your insurer if you are insured by a health 
insurance company (you should ask your insurer if you have any questions regarding 
your insurer’s willingness to pay under these circumstances). 
A co-payment/deductible from you may be required by your insurer or Medicare/Medicaid 
even if your insurer or Medicare/Medicaid has agreed to pay the costs).  The amount of 
this co-payment/deductible may be substantial. 
You do not give up your legal rights by signing this form. 
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WILL YOU RECEIVE ANY REWARDS FOR TAKING PART IN THIS STUDY? 
You will not receive any rewards or payment for taking part in the study.  However, if you 
are interested, we can provide you with a standardized exercise program to address any 
strength and motion deficits you may have.  
WHAT IF YOU HAVE QUESTIONS, SUGGESTIONS, CONCERNS, OR COMPLAINTS? 
Before you decide whether to accept this invitation to take part in the study, please ask 
any questions that might come to mind now.  Later, if you have questions, suggestions, 
concerns, or complaints about the study, you can contact the investigator, Mary Fisher at 
937-238-0633.  If you have any questions about your rights as a volunteer in this 
research, contact the staff in the Office of Research Integrity at the University of Kentucky 
at 859-257-9428 or toll free at 1-866-400-9428. We will give you a signed copy of this 
consent form to take with you. 
WHAT IF NEW INFORMATION IS LEARNED DURING THE STUDY THAT MIGHT 
AFFECT YOUR DECISION TO PARTICIPATE? 
If the researcher learns of new information in regards to this study, and it might change 
your willingness to stay in this study, the information will be provided to you.  You may be 
asked to sign a new informed consent form if the information is provided to you after you 
have joined the study.  
WHAT ELSE DO YOU NEED TO KNOW? 
You will be told if any new information is learned which may affect your shoulder or arm, 
or influence your willingness to continue taking part in this study. 
 
_____________________________________________                 ____________ 
Signature of person agreeing to take part in the study            Date 
  
_____________________________________________ 
Printed name of person agreeing to take part in the study 
  
_____________________________________________     ____________ 
Name of [authorized] person obtaining informed consent            Date 
  
_________________________________________ 
Signature of Investigator   
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Appendix C 
INTERNATIONAL PHYSICAL ACTIVITY 
QUESTIONNAIRE 
(August 2002) 
 
SHORT LAST 7 DAYS SELF-ADMINISTERED 
FORMAT 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 
questionnaires. Long (5 activity domains asked independently) and short (4 
generic items) versions for use by either telephone or self-administered methods 
are available. The purpose of the questionnaires is to provide common 
instruments that can be used to obtain internationally comparable data on 
health–related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in 
Geneva in 1998 and was followed by extensive reliability and validity testing 
undertaken across 12 countries (14 sites) during 2000.  The final results suggest 
that these measures have acceptable measurement properties for use in many 
settings and in different languages, and are suitable for national population-
based prevalence studies of participation in physical activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is 
encouraged. It is recommended that no changes be made to the order or wording 
of the questions as this will affect the psychometric properties of the instruments.  
 
Translation from English and Cultural Adaptation 
Translation from English is supported to facilitate worldwide use of IPAQ. 
Information on the availability of IPAQ in different languages can be obtained at  
www.ipaq.ki.se. If a new translation is undertaken we highly recommend using 
the prescribed back translation methods available on the IPAQ website. If 
possible please consider making your translated version of IPAQ available to 
others by contributing it to the IPAQ website. Further details on translation and 
cultural adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical 
Activity Prevalence Study is in progress. For further information see the IPAQ 
website.  
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More Information 
More detailed information on the IPAQ process and the research methods used 
in the development of IPAQ instruments is available at www.ipaq.ki.se and 
Booth, M.L. (2000).  Assessment of Physical Activity: An International 
Perspective.  Research Quarterly for Exercise and Sport, 71 (2): s114-20.  Other 
scientific publications and presentations on the use of IPAQ are summarized on 
the website. 
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INTERNATIONAL PHYSICAL ACTIVITY 
QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that 
people do as part of their everyday lives.  The questions will ask you about 
the time you spent being physically active in the last 7 days.  Please 
answer each question even if you do not consider yourself to be an active 
person.  Please think about the activities you do at work, as part of your 
house and yard work, to get from place to place, and in your spare time for 
recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  
Vigorous physical activities refer to activities that take hard physical effort 
and make you breathe much harder than normal.  Think only about those 
physical activities that you did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous 
physical activities like heavy lifting, digging, aerobics, or fast 
bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical 
activities on one of those days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  
Moderate activities refer to activities that take moderate physical effort 
and make you breathe somewhat harder than normal.  Think only about 
those physical activities that you did for at least 10 minutes at a time. 
 
3. During the last 7 days, on how many days did you do moderate 
physical activities like carrying light loads, bicycling at a regular 
pace, or doubles tennis?  Do not include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
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4. How much time did you usually spend doing moderate physical 
activities on one of those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes 
at work and at home, walking to travel from place to place, and any other 
walking that you might do solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 
10 minutes at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those 
days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during 
the last 7 days.  Include time spent at work, at home, while doing course 
work and during leisure time.  This may include time spent sitting at a 
desk, visiting friends, reading, or sitting or lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a 
week day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
This is the end of the questionnaire, thank you for 
participating. 
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Appendix D 
FACT-B 
Below is a list of statements that other people with your illness have said 
are important. Please circle or mark one number per line to indicate 
your response as it applies to the past 7 days. 
PHYSICAL WELL-BEING 
 Not at 
all 
A little 
bit 
Some- 
what 
Quite a 
bit 
Very 
much 
I have a lack of energy 0 1 2 3 4 
I have nausea 0 1 2 3 4 
Because of my physical condition, I 
have trouble 
meeting the needs of my family 
0 1 2 3 4 
I have pain 0 1 2 3 4 
I am bothered by side effects of 
treatment 
0 1 2 3 4 
I feel ill 0 1 2 3 4 
I am forced to spend time in bed 0 1 2 3 4 
 I feel ill 0 1 2 3 4 
I am forced to spend time in bed 0 1 2 3 4 
 
 
 
 
SOCIAL/FAMILY WELL-BEING 
 Not at 
all 
A little 
bit 
Some- 
what 
Quite a 
bit 
Very 
much 
I feel close to my friends 0 1 2 3 4 
I get emotional support from my family 0 1 2 3 4 
I get support from my friends 0 1 2 3 4 
My family has accepted my illness  0 1 2 3 4 
I am satisfied with family 
communication about my 
illness 
0 1 2 3 4 
I feel close to my partner (or the person 
who is my main 
support) 
0 1 2 3 4 
Q1 Regardless of your current level of 
sexual activity, please answer the following 
question. If you prefer not to answer it, 
please mark this box and go to the next 
section. 
     
 I am satisfied with my sex life 0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as 
it applies to the past 7 days. 
 
EMOTIONAL WELL-BEING 
 Not at 
all 
A little 
bit 
Some- 
what 
Quite a 
bit 
Very 
much 
I feel sad 0 1 2 3 4 
I am satisfied with how I am coping 
with my illness 
0 1 2 3 4 
I am losing hope in the fight against my 
illness 
0 1 2 3 4 
I feel nervous 0 1 2 3 4 
I worry about dying 0 1 2 3 4 
I worry that my condition will get worse 0 1 2 3 4 
 
 
FUNCTIONAL WELL-BEING 
 Not at 
all 
A little 
bit 
Some- 
what 
Quite a 
bit 
Very 
much 
I am able to work (include work at 
home) 
0 1 2 3 4 
My work (include work at home) is 
fulfilling 
0 1 2 3 4 
I am able to enjoy life 0 1 2 3 4 
I have accepted my illness 0 1 2 3 4 
I am sleeping well 0 1 2 3 4 
I am enjoying the things I usually do for 
fun 
0 1 2 3 4 
I am content with the quality of my life 
right now 
0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as 
it applies to the past 7days. 
 
 
ADDITIONAL CONCERNS 
 Not at 
all 
A little 
bit 
Some- 
what 
Quite a 
bit 
Very 
much 
I have been short of breath 0 1 2 3 4 
am self-conscious about the way I 
dress 
0 1 2 3 4 
One or both of my arms are swollen or 
tender 
0 1 2 3 4 
 I feel sexually attractive 0 1 2 3 4 
I am bothered by hair loss 0 1 2 3 4 
I worry that other members of my 
family might 
someday get the same illness I have 
0 1 2 3 4 
I worry about the effect of stress on my 
illness 
0 1 2 3 4 
I am bothered by a change in weight 0 1 2 3 4 
I am able to feel like a woman 0 1 2 3 4 
I have certain parts of my body where I 
experience pain 
0 1 2 3 4 
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Appendix H 
PHYSICAL ACTIVITY APPRAISAL INVENTORY (PAAI) 
 
Directions: Using the 0-100 scale below, please rate how sure you are that you 
can perform your usual physical activities regularly under the following 
conditions. Physical activity refers to all activity at home, work, or leisure.  
0 10  20  30  40 50  60  70  80  90  100  
Cannot            Moderately     Certain  
do at all          certain can do     can do  
I am confident that I can perform my usual physical activities (includes all 
activity at home, work, or leisure): (0-100)  
 
1. When I am feeling tired _____  
2. When I am feeling pressure from work or school ______  
3. During bad weather ______  
4. During or after experiencing personal problems ______  
5. When I am feeling depressed ______  
6. When I am feeling anxious ______  
7. When I feel physical discomfort with an activity 
8. When I have too much work to do at home ______  
9. When I/we have visitors ______  
10. When there are other interesting things to do _____  
11. When I don’t have support from my family or friends ______  
12. When I have other time commitments ______  
13. When I do not feel well ______   
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